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Background: Schistosomiasis remains a public health threat in sub-Saharan Africa which 
carries 85% of the global burden. With effective vaccines a distant future away, and no one all-
round intervention, research is still required to ensure that only effective programmes are 
introduced and implemented as well as evaluated and/or monitored. It is therefore key for 
researchers, policy makers and implementers to understand the epidemiology, immunology, 
immunopathology, immunogenetics, chemotherapy, management and control of Schistosoma 
haematobium for optimal elimination strategies to be implemented. A research study was 
therefore instituted to determine the prevalence, risk factors and host immunogenetic factors in 
S. haematobium infections among pre- and school going children living in endemic regions of 
Manicaland and Mashonaland central provinces in rural Zimbabwe. The relationship between 
single nucleotide polymorphisms (SNPs) of the promoter regions of tumor necrosis factor alpha 
(TNF-α or rs1800629) and interleukin- 10 (IL-10 or rs1800871) and susceptibility to 
Schistosoma haematobium was investigated.  In addition, the relationship between these SNPs 
and cytokine levels, as well as the relationship between actual cytokine levels and susceptibility 
to Schistosoma haematobium was assessed.  
Methods: In this cross-sectional immune-epidemiological study Schistosoma haematobium 
was diagnosed by the microscopic examination of urine specimens for the presence of parasite 
eggs using the urine filtration technique. DNA for the genotyping was extracted from 
approximately 300μl whole blood using the QiagenFlexiGene DNA extraction kit, following 
the manufacturer’s protocol. IL-10 and TNF-α promoter region single nucleotide 
polymorphisms were genotyped using amplification refractory mutation system-polymerase 
chain reaction (ARMS-PCR).The allele frequencies and genotype distribution of S. 
haematobium infected and uninfected participants were then analysed using the chi-square test. 
All analyses were performed using SPSS (version 21) and p-values <0.05 were considered 
statistically significant. The levels of the cytokines (IL-10 and TNF-α) were measured by 
indirect enzyme linked immunosorbent assay (ELISA) using MABTECH, 3510-1H-6 kits, 
according to the manufacturer’s instruction. 
Results: The overall prevalence of S. haematobium among children in endemic rural and 
farming communities of the two provinces of Zimbabwe assessed was 17.1% (158/924). 
Gender specific prevalences were similar (17.5% in girls and 16.7% in boys; p = 0.735). Age 
and location were significant risk factors for schistosomiasis in children living in endemic 
regions surveyed. The older the child the higher the risk of getting infected by S. haematobium 
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(10.5% in 0-5 year olds; 24.0% in 6-10 year olds and 30.7% in 11-15 year olds; p < 0.001).  
IL-10 -1082 G/A, IL-10 -819 C/T and TNF-α -308 G/A single nucleotide polymorphisms were 
not significantly associated with susceptibility to S. haematobium infection. TNF- α genotypes 
AA, GA and GG were associated with high, moderate to high and low production of TNF-α 
respectively. IL-10 TT, CT and CC genotypes were associated with low, moderate and high 
IL-10 plasma levels respectively. Higher TNF-α and lower IL-10 serum levels were negatively 
associated with schistosomiasis infection. Praziquantel treatment reduced prevalence among 
the study participants as reinfections were only recorded in 6 of the 59 (10.2%) who were 
infected at baseline of children.  
Discussion and Conclusion: The determined schistosomiasis prevalence puts the regions of 
Zimbabwe studied within the moderate range as described by the World Health Organisation 
(10 – 49% prevalence), hence more concerted efforts are required to fight schistosomiasis. 
Although cytokine genotypes were associated as expected with cytokine levels, genotypes did 
not directly correlate with schistosomiasis infection while cytokine levels did.  This indicates 
that circulating TNF-α and IL-10 levels are a result of many factors apart from genotypes. 
Taken together with previous work, this study suggests that high TNF-α and low IL-10 serum 
levels confer protection against schistosomiasis infection. Since schistosomiasis prevalence 
was similar between boys and girls and prevalence was high in all age groups (increasing with 
age), all programmes aimed at eliminating schistosomiasis should include both genders and 
children of all age groups.  Specific locations could be targeted in resource limited settings as 
location was a significant risk factor for infection. Praziquantel is effective, with few 
reinfections observed, and therefore remains central in schistosomiasis management. To clearly 
understand the role host genetic factors in infection and to inform effective control, elimination 








INTRODUCTION AND LITERATURE REVIEW 
1.1. Helminths: History and Classification of Schistosomes 
The word helminths comes from a Greek word, hélmins, which means a kind of a worm. 
Helminths have afflicted humans since prehistorical and biblical times and their eggs have been 
found in mummified bodies dating thousands of years ago (Hotez et al. 2008). They fall into 
the phyla Nematoda (roundworms) and Platyhelminthes (flatworms) and are very important 
and notorious human and animal parasites (Brindley et al. 2009). Not all is negative though - 
for example, history has it that schistosome flatworms saved Formosa, the nowadays Taiwan, 
from Mao’s troops when acute schistosomiasis sickened them long enough for the Americans 
to arrive (Hotez et al. 2008). Geo-redistribution has left helminths now unduly afflicting 
populations from marginalized, low-income and resource-constrained portions of the world 
such as sub-Saharan Africa, Asia and the southern Americas, where at any given time over a 
billion people are infected by at least one helminth species (WHO 2012).  
Diseases caused by helminths form part of the neglected tropical diseases (NTDs) as defined 
by the World Health Organisation (WHO), and research within the affected communities has 
shown that parasitic helminths contribute to morbidity, allergic diseases, stunted growth in 
children, enhanced transmission and progression of HIV/AIDS and malaria, chronic anaemia, 
unbearable public health and budgetary burdens, poverty, low economic growth, disabilities, 
and infertility, among other negative consequences (Evans and Stephenson 1995; Crompton et 
al. 2003; Brindley et al. 2009; WHO 2012; Lwanga et al. 2012; Helmby 2015).  
Acute or chronic schistosomiasis (bilharzia) is caused by parasitic dimorphic Schistosoma 
trematode worms, belonging to the phylum Platyhelminthes, which infect humans who come 
into contact with infested waters as they carry-out their routine agricultural, domestic, 
occupational and recreational activities (Adenowo et al. 2015; Mupakeleni et al. 2017). Five 
species, namely Schistosoma mansoni, Schistosoma haematobium, Schistosoma japonicum, 
Schistosoma mekongi and Schistosoma intercalatum, are known to infect humans but only S. 
mansoni and S. haematobium are of importance to sub-Saharan Africa (Adenowo et al. 2015). 
Schistosoma haematobium causes urinary schistosomiasis, while S. mansoni causes intestinal 
schistosomiasis (Sady et al. 2013). 
2 
 
Schistosomiasis was first described as a human disease in 1851 by a German physician Theodor 
Bilharz hence the name bilharzia (Chimbari 2012). Bilharz discovered S. haematobium during 
autopsy at  Kasr El Ainy hospital, Egypt (Barakat 2013; Jourdan 2013). The description has 
led to the study of its life cycle. Leiper fully described the schistosome’s life cycle in 1915 
(Barakat 2013). Endemicity of schistosomiasis in Egypt can be traced back to the Pharaohs’ 
times as shown by the presence of calcified ova/eggs in the Egyptian mummies (Mostafa et al. 
1999). Symptoms and signs consistent with schistosomiasis have been found in Egyptian 
papyrus fragments that date back to 1900BC (Jourdan 2013). Ruffer in 1910 was the first to 
diagnose S. haematobium infections in mummies dating back to the 20th Dynasty (Barakat 
2013). ELISA was used to identify S. haematobium in two mummies aged over 3000 and 4000 
years (Barakat 2013). In Zimbabwe schistosomiasis has persisted since 1909. Estimates of 
1961 suggest that as many as 80% of black Zimbabweans were affected (other races were also 
affected but at much lower rates) (Sokolow 2016).   
1.2. Life Cycle of Schistosomes 
Understanding clearly the life cycle of schistosomes is of paramount importance if effective 
management and control policies are to be crafted. The parasite has a complex life cycle bearing 
well-adapted stages for free-living as well as for life in the intermediate host (snails) and 
definitive host (vertebrates), where they mature into male or female worms in the host’s veins 
(Walker 2011; Colley et al. 2014). Adult male–female schistosome pairs reside in the 
mesenteric veins (S. mansoni) and lay eggs, which sustain both transmission and pathology 
(Olliaro et al. 2014). Those schistosome pairs can survive in human veins laying eggs for 3-10 
years or even several decades (Colley and Secor 2014).  
The eggs secreted via faeces or urine contaminate the environment. When trapped in the 
definitive host’s tissues they cause inflammation and eventually die. Those that get into the 
environment, if they reach fresh water, hatch into ciliated miracidia which upon infecting a 
suitable intermediate snail host develop and reproduce asexually to produce thousands of 
cercariae.  Cercariae released into water are ready to infect humans (FIGURE 1.1) (Colley and 
Secor 2014). Cercariae, which penetrate human skin, mature into egg producing females and 
males in 5-7 weeks. Eggs usually just have a 1-2 week life-span (Colley and Secor 2014). 
TABLE 1.1 compares S. haematobium and S. mansoni in terms of key features in the 








Table 1.1: Comparison of key features in schistosome life cycles (Meurs 2014) 
Description S. haematobium  S. mansoni  





Definitive host Human Human (also primates and 
rodents) 
Location adult worm Veins of the pelvis Veins of the mesenteric plexus 







Urinary and genital Intestinal and hepatic 
Geographic 
distribution 
Africa and Middle East Africa, Middle East, Caribbean 
and South America 
1.3.Clinical Features and Outcome of Schistosomiasis  
Symptoms of schistosomiasis include weakness, haematuria and proteinuria (urinary 
schistosomiasis), diarrhoea, hepatosplenomegaly and carcinoma of the intestine, liver, uterus 
and bladder (TABLE 1.2 and TABLE 1.3 show clinical phases and discrete or common 
symptoms, respectively) (Mostafa et al. 1999). Schistosomiasis impairs cognitive 
development, hence it interferes with the ability of children to achieve much in school and life 
in general. Blood loss and nutrient absorption impairment may lead to anaemia, especially with 
higher intensities of infection (Midzi et al. 2014; Friedman et al. 2017). Urinary schistosomiasis 
has been linked to increased HIV infections due to chronic inflammation and possible 
ulcerations. Other consequences of urinary schistosomiasis are low birth weights if it affects 
pregnant women, low worker productivity and poor socio-economic development (Midzi et al. 
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2014; Friedman et al. 2017). Undernutrition through suppression of appetite and inflammation-
mediated cachexia are reported as a consequences of schistosomiasis (Friedman et al. 2017).  
Table 1.2: Clinical phases and symptoms of schistosomiasis (Vale et al. 2017) 
Phase  Symptoms  
Immediate  Acute, pruritic and maculopapular eruption at site of cercarial skin penetration 
within 1 day following exposure 
Acute  Systematic hypersensitivity reaction against migrating schistosoma, fever, 
fatigue, myalgia, malaise, non-productive cough, eosinophilia, patchy 
infiltrates, weight loss, dyspnoea, diarrhoea, diffuse abdominal pain, 
toxaemia, hepatosplenomegaly, widespread rash 
Chronic  Affects gastrointestinal and urogenital tracts, leading to hepatosplenic and 
pelvic organ diseases, portal and pulmonary hypertension, abdominal ascites, 
upper gastrointestinal varices and haemorrhage, female genital 
schistosomiasis, infertility, increased risk of HIV-1 transmission and 















Table 1.3: Discrete and shared effects of S. haematobium and S. mansoni (Ogden et al. 2013) 
S. mansoni 
(Hepato-Intestinal Schistosomiasis) 
Shared effects S. haematobium 
(Urogenital Schistosomiasis) 
 Abdominal pain  
 Diarrhoea  
 Blood in stool  
 Liver, spleen enlargement in 
advanced cases  
 Can result in death  
 
Fatigue and malaise: 
 Reduced ability 
to concentrate 
and learn  
 Reduced 
productivity and 
economic gains  
 
 Blood in urine  
 Female genital 
schistosomiasis: lesions of 
the cervix and vagina, vaginal 
bleeding and pain during 
sexual intercourse; a risk 
factor for sexually 
transmitted infections  
 Men: pathology of the 
seminal vesicles, prostate and 
other organs, leading to 
infertility and possible 













Schistosomiasis can also be classified as light, moderate and heavy infection based on egg 
counts per sample (urine or faeces) (TABLE 1.4). 
Table 1.4: Classification of infection intensities (Meurs 2014) 
Class S. haematobium (eggs per 10ml urine) S. mansoni (eggs per gram of stool) 
Light  1 – 10 1 – 99 
Moderate  11 – 49  100 – 399 
Heavy  50 ≤ 400 ≤ 
 
1.4. Epidemiology and Morbidity of Schistosomiasis  
Schistosomiasis is one of the most prevalent NTDs, with schistosomes  infecting between 200 
to 300 million people worldwide, mostly in poverty stricken regions in the tropics and 
subtropics (FIGURE 1.2) (Sady et al. 2013; Colley and Secor 2014; Midzi et al. 2014; Swartz 
et al. 2015; Senghor et al. 2015; Sokolow et al. 2017; Mupakeleni et al. 2017). More than 90% 
of about 790 million people at risk of schistosome infection worldwide are in sub-Saharan 
Africa (Sady et al. 2013; Sokolow et al. 2017). Together with geo-helminths and excluding 
malaria, schistosomes account for 40% of the disease burden in the tropics (Adenowo et al. 
2015).  
The public health importance of schistosomiasis in Zimbabwe cannot be overemphasized as it 
has been in the top ten of diseases causing hospital visits and/or admissions for decades 
(Chimbari 2012). Of all the schistosomes, S. haematobium is the most common parasite in sub-
Saharan Africa causing urinary schistosomiasis or bilharzia (Mutapi et al. 2007).   In Zimbabwe 
S. haematobium is more widely distributed in the Matabeleland South province and dam 
construction has led to many changes to the distribution patterns country wide (Chimbari 
2012). In 2012 the prevalences of S. haematobium and S. mansoni were 20.8% and 9% 
respectively. In 2014 overall schistosomiasis prevalence was found-out to be 22.7% (S. 
haematobium 18% and S. mansoni 7.2%, where some individuals were coinfected). The fall in 
prevalences can be attributed to various interventions such as mass drug administrations 
(MDAs), health promotion and/or education and vector control as a result of the renewed 




Figure 1.2: Global distribution of Schistosomiasis. From The Lancet Vol. 368, Gryseels et al., 
‘Human schistosomiasis’, pages 1106-18, 2006 as cited by Meurs (Meurs 2014) 
Estimates by WHO in 2014 suggests that as many as 40 million women of reproductive age 
were infected by schistosomiasis (Friedman et al. 2017). In Zimbabwe, in general, 
schistosomiasis affects boys more than girls and children more than adults due to chores 
(fetching of water and washing of clothes – FIGURE 1.3) and recreational 
activities/behaviours (swimming) (Sokolow 2016). School-age children are important in the 
transmission of schistosomes due to unhygienic defecation/urination habits. Many factors have 
been linked to transmission of schistosomes, namely climatic changes (higher ambient 
temperatures increased parasitic burden), proximity to water sources, lack of knowledge, age 
range, man-made ecological changes for example dams and other water reservoirs and socio-
economic status (Moyo and Taonameso 2005; Chimbari 2012; Adenowo et al. 2015; Kabuyaya 




Figure 1.3: Contact with possibly contaminated water due to chores related activities, exposes 
children and women to Schistosoma (Mduluza and Mutapi 2017) 
Coinfections of S. haematobium and S. mansoni are also common and they lead to within host 
interactions that may alter disease course. The interactions are based on possible competition 
for nutrients and mates (infertile pairs) as well as cross-activation of the immune responses 
(Knowles et al. 2015). Different liver and bladder morbidities often results from such mixed 
infections (Knowles et al. 2015). As highlighted above, the negative impact attributable to 
schistosome infection alone includes chronic anaemia, low birth weights, growth stunting, 
cognitive impairment, infertility, fatigue, low work productivity and increased susceptibility to 
co-infections, including sexually transmitted infections such as HIV (Midzi et al. 2014; Swartz 
et al. 2015). Schistosomiasis together with malaria and soil-transmitted helminthic infections 
is linked to high maternal and child morbidity and mortality, anaemia and malnutrition in sub-
Saharan Africa (Sousa-figueiredo et al. 2012). Polyparasitism, leading to synergistic 
interactions and more detrimental health consequences, is not uncommon as these parasitic 
infections often overlap geographically (Sousa-figueiredo et al. 2012). 
1.5. Diagnosis of Schistosomiasis  
Standard diagnosis of schistosomiasis involves the detection of viable eggs in urine (S. 
haematobium), faeces (S. mansoni and S. japonicum) or tissue biopsies (Colley et al. 2014; 
Mduluza et al. 2017). Thus prevalence in populations is also estimated using the Kato-Katz 
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faecal smear (S. mansoni) and urine filtration and/or questionnaires for visible haematuria (S. 
haematobium). These traditional ways of diagnosis while efficient in areas of high endemicity 
are however less sensitive in people with low levels of infection (Nausch et al. 2014). 
Biomolecular methods, for example the detection of parasite specific DNA in urine (such as 
PCR Dra1 tandem repeats detection), if optimized for field use will be essential in 
schistosomiasis elimination. Antibody based methods can be highly sensitive and specific. 
These can be easily optimized and put into cheaper rapid diagnosis test (RDT) kits for wider 
field and point of care (POC) applications especially for resource limited settings. Some useful 
and commercially available POC tests for schistosomiasis include reagent strips for detection 
of micro-haematuria (e.g. Hemastix ®, Combur 10 Test® strips and Medi test combi 9) and the 
POC circulating cathodic antigen (CCA) test (Rapid Medical Diagnostics, Pretoria, South 
Africa) (Nausch et al. 2014). Each has its advantages and disadvantages for example CCA is 
sensitive to S. mansoni and less so to S haematobium and relatively costs more (Nausch et al. 
2014).  
Other effective techniques include S. mansoni cercarial transformation fluid (SmCTF) which 
detects anti-schistosome antibodies in human blood and schistosome soluble egg antigens 
enzyme-linked immunosorbent assays (SEA-ELISA). These test though needing more 
evaluations they have given hope for RDTs in rapid prevalence mapping of S. mansoni and S. 
haematobium in schistosome-endemic areas (Nausch et al. 2014). Schistosoma haematobium 
can be diagnosed easily and relatively cheaper using a useful and sensitive ELISA based 
antibody detection method from urine (Elkawaz and Ghaffarifar 2009).  
1.6. Management and Control of Schistosomiasis  
There are four basic ways of intervention in the control and/or management of schistosomiasis 
namely: 
1. Treatment of infected individuals which removes and/or reduces morbidity, mortality 
and environmental contamination levels of schistosome eggs. 
2. Proper sanitation that also reduces environmental contamination as well as minimizes 
the chances of miracidia finding and/or penetrating the schistosome’s intermediate 
hosts i.e. snails. 
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3. Control of intermediate snail hosts by biological, physical and/or chemical methods e.g. 
through the use of ducks and prawns thus significantly reducing the levels of cercariae 
available to infect humans.  
4. Provision of and access to safe water minimises chances of cercariae finding the 
definitive hosts (i.e. humans) in its limited lifespan (Chimbari 2012).   
Countries and regions may have different emphasis on each and one of the above mentioned 
approaches to control schistosomiasis. The WHO emphasises the treatment of infected 
individuals. Also some approaches are not applicable in some settings because of logistical, 
financial and/or environmental reasons for example chemical control of snails is not practical 
in communal areas (Chimbari 2012).  Combining two or more strategies often produces better 
results like what was done in Hippo Valley Sugar Estates, Zimbabwe where chemical and 
biological control of snails was combined with treatment of the infected individuals. The 
resultant reduced prevalence persisted for decades after the end of the program (Sokolow 
2016).  
1.6.1. Intermediate Host Control  
Vector control is based on snail killing through use of pesticides or chemicals like niclosamide, 
habitat changes, predators (for example use of prawns) and biological competitors (Colley et 
al. 2014; Swartz et al. 2015; Sokolow et al. 2017). Schistosoma mansoni and S. haematobium 
parasites are transmitted through their intermediate snail hosts Biomphalaria pfeifferi and 
Bulinus globosus, respectively, with both snail species common in most bodies of fresh water 
(Knowles et al. 2015; Sokolow 2016). Niclosamide can be used to control of intermediate host 
populations although it is not effective or applicable in communal settings (Chimbari 2012). 
Thiara (Tarebia) granifera (Lamarck) a Prosobranch snail can in a time dependent fashion 
suppress Biomphalaria the intermediate host snails for S. mansoni(Sodeman 1991). The other 
competitor snail that was used in Zimbabwe is  Bulinus tropicus (Sokolow 2016).  
Ducks are also useful as biological predators of the intermediate snail hosts of schistosomes. 
Molluscicides derived from plant sources such as Phytollacca dodecandra and Jatropha curcas 
have been shown to be extremely potent in controlling snails although community practicality 
is still a significant challenge. Prawns and fish (Cichlid species, Sargochromis codringtonii) 
have also been shown to be effective in controlling schistosome’s intermediate snail hosts; 
however the fish does not necessarily prefer the snails and vegetation in the water bodies can 
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hinder their effectiveness (Sokolow 2016).  Furthermore the predator-prey equilibrium may 
limit effectiveness of biological interventions (Chimbari 2012).  
1.6.2. Safe Water and Sanitation  
Provision of clean safe water and sanitation helps not only in schistosomiasis control but also 
in many other NTDs or communicable infections like soil-transmitted helminths, cholera, 
typhoid and dysentery (Chimbari 2012). By 2015, 76.9% of Zimbabweans had access to 
improved drinking water and only 36.8% had access to improved sanitation (Sokolow 2016). 
This further highlights significant work still to be done, especially in the sanitation front, if 
Zimbabwe is to eliminate schistosomiasis.  
1.6.3. Chemotherapy in Schistosomiasis: Praziquantel   
Antimony potassium tartrate (APT) is the oldest recorded anti-schistosome drug dating back 
to 1605 (Trainor-Moss and Mutapi 2016). Orally administered drugs useful nowadays are 
metrifonate (effective against urinary schistosomiasis and reduces hookworm bio-burdens) and 
praziquantel (effective against both urinary and intestinal schistosomiasis and other helminths) 
(Evans and Stephenson 1995; Mduluza et al. 2017).  Because praziquantel (PZQ) is relatively 
safe (even in pregnancy, nursing mothers, children and geriatric patients), effective against all 
mature/adult Schistosoma species, and easily administered at relatively low cost, it is the drug 
of first choice (Colley et al. 2014). The costs of treating one patient has fallen as from the 1990s 
from approximately $4 to about $0.30; affording large scale community PZQ administrations 
(Koukounari et al. 2007). The drug was discovered in Germany by Bayer; was first developed 
for veterinary use and later for humans (Reich and Govindaraj 1998).  
It is estimated that in 2018 as many as 235 million people will be treated using PZQ equating 
to around 645 million PZQ tablets used (Olliaro et al. 2014).  PZQ can be used yearly or 
regularly in children alone or in conjunction with other drugs managing other parasitic 
infections, and it can be used through school- or community-based mass drug administration 
programs, independent of reinfections levels, as preventative and/or morbidity control efforts 
(Colley et al. 2014). As noted above preventative chemotherapy alone is not enough other 
strategies mentioned above (vector control, hygiene and sanitation, health promotion and 
educations) are employed in the effort to eliminate schistosomiasis and other helminthic 
infections (Midzi et al. 2014).  
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PZQ is effective given either as a single or divided dose, usually at night after food to minimize 
side effects and enhance absorption (Castro et al. 2002; Lima et al. 2011; Alsaqabi and Lotfy 
2014). It usually comes as a 600mg tablet divided into quarters. The fact that it is taken orally 
(mimicking normal feeding activities) and as a single dose means compliance is high. It has a 
bitter taste but is often masked by excipients thus it is supposed to be swallowed whole to avoid 
the bitterness. These factors makes PZQ well suited for field and/or mass drug administration 
usage. The accepted dosage world-over, with cure rate ranging between 60-95%, is 40mg/kg 
body weight (Kallestrup et al. 2006). The drug is manufactured as a racemic mixture of R and 
S enantiomers (Meister et al. 2016). Chemically PZQ is a synthetic heterocyclic isoquinoline-
pyrazine derivative known as 2-(cyclohexylcarbonyl)-1,2,3,6,7, 11b-hexahydro-4H-pyrazino 
[2, 1-a] isoquinolin-4-one (Masimirembwa et al. 1993; Moore 2012; Alsaqabi and Lotfy 2014) 
with the molecular formula C19H24N2O2 and structural formula given in FIGURE 1.4.  
 
Figure 1.4: Structural formulas of R - praziquantel, S – praziquantel, artemisinin and 
artesunate respectively (Masimirembwa 2013; Chan et al. 2017; Olliaro et al. 2014) 
The enantiomer R-PZQ is believed to be the one with the antischistosomal activity, while the 
inactive S-PZQ is suspected to be responsible for the unnecessary doubling of the tablet size, 
bitter taste and the mild to moderate adverse events of PZQ treatment (Reinhard-Rupp and 
Klohe 2017; Kovač et al. 2017; Olliaro et al. 2014; Meister et al. 2016; Chan et al. 2017; 
Mduluza and Mutapi 2017). Because it has been demonstrated that enantiomerically pure R-
PZQ can be economically produced, it is envisaged that such a formulation will be better 
acceptable, especially for children (Olliaro et al. 2014; Reinhard-Rupp and Klohe 2017; 
Mduluza and Mutapi 2017). Some studies have however shown that S-PZQ may have 
significant activity against S. haematobium (Kovač et al. 2017).  
1.7. Immunobiology and Pathogenesis of Schistosomiasis  
Acute schistosomiasis is rare in people living in endemic areas possibly due to pre- and 
postnatal exposures. The acute syndrome, also known as Katayama fever, is often accompanied 
by cercarial dermatitis which also mostly associated with heavy infections in tourists (Boros 
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1989; Burke et al. 2009). It is characterised by fever, malaise, hepatosplenomegaly, 
eosinophilia, diarrhoea, and, in some cases, oedema, urticaria, lymphadenopathy and arthralgia 
(Boros 1989).  
Immune responses to schistosome infections can be viewed in many facets, namely 
immunopathogenesis, resistance to reinfection, and immunodiagnostics (Colley et al. 2014; 
Mduluza et al. 2017). The first 3-5 weeks of exposure to immature parasites is characterised 
by type 1 immune response activation leading to the increased Th1 cells and release of IL-12 
and interferon (IFN)-ᵧ (Hams et al. 2013).  As the parasite matures and start producing eggs 
(from 5-6 weeks), the immune response shifts to predominantly type 2 kick-starting chronic 
schistosomiasis. IL10 is thought to be key to the Th1 to Th2 switch (Burke et al. 2009). Chronic 
schistosomiasis is the most prevalent form of bilharzia in endemic areas as repeated exposures 
leads to reinfections (Colley et al. 2014). TABLE 1.5 shows some notable pathology, signs 
and symptoms of schistosomiasis depending on the infecting schistosome.  
Table 1.5: Pathology of human schistosomiasis (Vale et al. 2017) 
Species Pathology, Signs and Symptoms  
S. haematobium Urogenital tract fibrosis, female genital schistosomiasis, bladder 
cancer, renal failure, infertility  
S. mansoni Liver/periportal fibrosis, hepatomegaly, intestinal fibrosis, diarrhoea 
 
The chronic disease is due to immunopathological reactions against trapped schistosome eggs 
in organs like the liver, intestines, bladder and the urogenital system (Madinga et al. 2015). 
This is because the schistosome eggs release highly antigenic glycoproteins collectively known 
as schistosoma egg antigen (SEA) through microscopic pores within the rigid egg shell, which 
then promote dominant Th2 immune responses (Boros 1989; Joshi et al. 2008). Schistosome 
eggs can be deposited in the intestinal tract, and liver, renal, pulmonary or central nervous 
systems leading to the granulomatous response (Boros 1989). As stated above, the immune 
responses are driven by Th2 through recruitment and activation of eosinophils, alternatively 
activated macrophages (or M2 macrophages), dendritic cells and CD4+ Th2 cells (Joshi et al. 
2008). The egg-antigen also leads to the production of IL-4, IL-5, IL-13 and immunoglobulin 
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(Ig) E (Hams et al. 2013). FIGURE 1.5 summarizes the components and cytokine 
contributions to granulomatous response.  
The type 2 immune response peaks with marked granulomatous inflammation around 
schistosome eggs. With chronic infection a state of hyporesponsiveness ensues characterised 
by dampening of Th2 responses leading to controlled chronic disease. This is in part as a result 
of a dynamic association between Th1, Th17 and T regulatory cells which regulates disease 
severity (Hams et al. 2013). Pro-inflammatory Th17 CD4+ T cells, which are implicated in 
other autoimmune disease like encephalomyelitis and collagen-induced arthritis, are also 
implicated in the granulomatous response. Fibrosis that follows the granulomatous 
inflammatory responses enhances the disease pathology contributing to mortality (Boros 1989; 
Joshi et al. 2008). Though this immune response is key for host survival, the resultant chronic 
granulomatous response is deleterious to any tissue containing those eggs. The granuloma, full 
of Th2 cells, eosinophils and M2 macrophages, acts to protect the surrounding host tissue from 
the toxins released by the egg, through providing a physical barrier between the egg and the 
tissue and sequestration of antigenic products secreted by the egg (Hams et al. 2013). Th2 
cytokines, including IL-4 and IL-13, promote immunopathology while IFN-γ protects against 
the development of severe fibrosis. Thus tight regulation of the Th1, Th2 and Th17 cytokine 
responses generated during schistosome infection is essential to prevent excessive pathology 




Figure 1.5: Major components of, main cytokines and chemokines that regulate the 
granulomatous response to schistosome eggs in the host liver (Burke et al. 2009). 
The development of protective immunity against schistosome is rather slow and the reasons 
behind such slowness are not yet clear. Some scientists postulate that dying parasites, which 
will be scarce given the longer lifespans of the worms, are the source of the protective antigens 
while others believe that the threshold for exposure to the necessary antigens for protective 
immunity to develop is rarely reached (Mitchell et al. 2012). Schistosomiasis immunity 
depends in part on intensity of infection- the higher the intensity of infection, the higher the 
chances of becoming resistant to schistosomes. Children often have higher burdens and are 
more likely to be reinfected than adults (Mduluza et al. 2001).  
Many scientists have linked some antibodies to the said protective immunity. Several studies 
in infected individuals have shown heterogeneity in terms of parasitic burdens and types or 
levels of anti-schistosome specific antibodies (such as IgG2a, IgM, IgG1 and IgG2b) (Mitchell 
et al. 2012), thereby linking antibodies to protective immunity. Studies in schistosomiasis 
endemic regions have linked few loci (SM1 of the 5q31-q33) to susceptibility to infection, 
reinfection, diseases and severity (Mangano and Modiano 2014). Those immuno-epidemiology 
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studies have also helped emphasise the importance of the host Th2-type immune response in 
susceptibility to schistosomiasis and other helminthic infections (Mangano and Modiano 
2014). Resistance to reinfection has consistently been associated with high levels of IgE 
antibodies against worm antigens, low concentrations of IgG4 antibodies to worm antigens and 
high levels blood eosinophilia (Colley et al. 2014). Treatment has been shown to help the 
development and maintenance of resistance to infection.  
1.8. Cytokine Polymorphisms and Schistosomiasis 
Different cytokine genotypes that may predispose individuals to severe inflammatory disease 
with worse clinical outcome exist in the populations, primarily due to the selective pressure of 
infectious diseases (Kube et al. 2003). Thus individual profiles for immuno-regulatory 
cytokines like IL-10, IFN-γ and TNF-α is key in determining outcomes of certain diseases 
(Kube et al. 2003). Polymorphisms in the genes encoding cytokine receptors have also been 
shown to correlate with increased susceptibility to infection or inflammatory conditions 
(Erikstrup et al. 2007; Brooks et al. 2008; Naicker et al. 2009; Shrestha et al. 2010). 
Furthermore, polymorphisms in the cytokine promoters greatly influence the levels of 
expression of the affected cytokine genes, are linked to certain autoimmune conditions and 
determine susceptibility to infections (Abel and Dessein 1997; Leornard 2000; Chatterjee et al. 
2009).  
Schistosomiasis disease severity has also been shown to be influenced by host genetic factors 
such as cytokine genotypes among other factors including coinfections, infection intensity and 
duration as well as nutritional status (Mduluza et al. 2017).   According to Hirayama (2005), 
higher frequencies of the HLADRB5* 0101 (B1*1501) allele (HLA class II gene) and IL-13 
promoter A/A (IL-13P A/A of IL-13 gene) genotypes are associated with severe fibrosis in 
chronic schistosomiasis (Hirayama 2005). 
The severity of schistosomiasis has also been shown to be influenced by cytokines/interleukins 
which regulate the inflammatory granuloma formation for example IL10, IL12, TNF-α and 
IFN-γ. Fibrosis that usually then follows was also shown to be under the influence of IL4, 
TGFβ1 and IFN-γ (Dessein et al. 1999). Other authors have also reported that TGF-β, IL1, 
IL13 and IL4 are fibrogenic and IL10 has regulatory role of controlling excessive Th1 and Th2 
polarization of the granulomatous response. IFN-γ and IL12 are protective against fibrosis 
while TNFα is thought to be either protective or proinflammatory (Henri et al. 2002). IFN-γ 
production by egg-antigen stimulated PBMCs correlates with protection against severe 
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schistosomiasis, and individuals with severe disease often have low production of the cytokine. 
IFN-γ is often associated with protection against peripheral fibrosis in humans while IL-10 
protects against severe hepatic central fibrosis (Burke et al. 2009).  
A Brazilian study provided evidence on strong gene influence on schistosome infection levels. 
The genes involved were mapped and shown to be in the 5q31-q33 chromosomal regions 
responsible for Th1/Th2 response regulation (Mduluza et al. 2017). The region has genes for 
IL4 (Th2 response promoter as well as cellular recruitment), IL5 (key in eosinophil 
recruitment) and IL13 (a profibrotic cytokine) (Burke et al. 2009). Two single nucleotide 
polymorphisms within the IL5 gene have been associated with development of schistosome 
symptomatic infection in Chinese population. Genes in the 6q22-q23 regions were shown to 
have influence in the hepatic fibrotic responses in S. mansoni chronic infection (Burke et al. 
2009). The region is associated with the IFN-γ receptor 1 gene encoding for the receptor of the 
antifibrogenic cytokine IFN-γ. Evidence exists for further association of schistosome infection 
levels, morbidity and/or mortality with IFN-γ receptor 1 subunit, major histocompatibility 
complex and other cytokine gene polymorphisms (Mduluza et al. 2017). Studies in Egypt also 
confirmed linkages of severe schistosomiasis with polymorphisms in the IFNGR1 locus and 
IL13/IL14 region as well as TGF-β1 gene (Burke et al. 2009). A study done in Brazilian 
patients failed to find association between IL-10 gene promoter region (G1082A/-C819T/-
C592A) polymorphisms and periportal fibrosis regression after specific treatment for 
schistosomiasis (Silva et al. 2016).  
A study done in Kenya confirmed the association between high production levels of TNF-α 
with exaggerated granulomatous response in the bladder wall/urinary tract pathology in 
children infected with S. haematobium (King et al. 2001). Other studies have also confirmed 
the aggravating effects of TNF-α and the protectiveness of IFN-γ in periportal fibrosis 
associated with chronic S. mansoni infection (Henri et al. 2002).  Collectively, these studies 
show that IL-10 and TNF-α among other cytokines play a major role in the pathogenesis and 
severity of schistosomiasis, and that host immunogenetics is paramount in determining 
susceptibility or resistance to schistosomiasis.  In addition, researchers in Kenya have shown 
that non-synonymous polymorphism in IL23R gene (rs1884444) renders protection against 
schistosomiasis-associated Immune Reconstitution Inflammatory Syndrome in patients 
receiving antiretroviral therapy (Ogola et al. 2014), indicating that host immunogenetics as also 




Interleukin (IL)-10 is an important anti-inflammatory T helper 2-type and T-regulatory type 
cytokine produced primarily by monocytes and lymphocytes (Imai et al., 2011; Mutapi et al., 
2011). Generally major sources of IL-10 varies from tissue to tissue or during acute or chronic 
stages of schistosomiasis. T helper 2 responses provide host protection against extracellular 
parasites such as S. haematobium but insufficient or little protection against the majority of the 
intracellular pathogens (Colley and Secor, 2014; Odegaard and Hsieh, 2014). T helper 2 
responses also tend to inhibit harmful T helper 1 inflammatory responses; as part of the down 
regulatory mechanism against exaggerated inflammatory responses (Odegaard and Hsieh, 
2014).  
IL-10 limits tissue damage (immunopathology) but interferes with pathogen clearance 
(Odegaard and Hsieh, 2014). Low IL-10 signalling may result in severe, often fatal 
immunopathology in schistosomiasis. Excessive production of IL-10 can also inhibit the T 
helper 1 immune response thus enhance immune evading by pathogens leading to conditions 
such severe anaemia associated with schistosomiasis. IL-10 is associated with high production 
IgG4 antibodies that block parasite specific IgE antibodies and susceptibility to schistosome 
infection; blocking IL-10 receptors has been shown to help in schistosomiasis treatment and 
protection against reinfection (Wilson et al., 2011; Colley and Secor, 2014).  
The human IL-10 gene is approximately 4.7 kb long on chromosome 1q21–32 and contains 
five exons that are separated by four introns (Mosser and Zhang, 2008). Five SNPs namely; -
3575, -2763, -1082, -819 and -592 tagging the promoter region of the gene have been widely 
studied (Mosser and Zhang, 2008). The homozygous wild type, GG, CC and CC of IL-10 
promoter positions -1082, -819 and -592 respectively, has been reported to be associated with 
high IL-10 production and protection against severe pathology (Guzowski et al., 2005; Zhang 
et al., 2012). The heterozygous condition and homozygous mutants (AA, TT and AA) 
associated with moderate and low IL-10 production respectively (Guzowski et al., 2005; Zhang 
et al., 2012).  
1.8.2. Tumour Necrosis Factor alpha 
Tumour Necrosis Factor alpha (TNF-α) is a 17 kDa potent immunomediator and 
proinflammatory cytokine produced by macrophages, monocytes, neutrophils, T cells and NK-
cells (Elahi et al., 2009; Tahan et al., 2016). TNF-α is reported to be important in apoptosis, 
migration of white blood cells to sites of infection, activation phagocytes and many other 
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important cellular processes such as proliferation, differentiation, growth and the immune 
response in general (Elahi et al., 2009; Tahan et al., 2016). Higher levels of TNF-α are 
associated with severe immunopathological conditions or complications as well as potent anti-
parasitic activity and rapid clearance of parasites such as schistosomes (Kubota et al., 1998; 
King et al., 2001).  
The human TNF-α gene is located on the short arm of chromosome 6 in a region of the major 
histocompatibility complex between the class 1 HLA-B and the class 2 HLA-DR loci (Kubota 
et al., 1998; Van Der Linden et al., 2001). Its full-length spans 2.76-kb and has four exons and 
three introns (Tu et al., 2018). Genetic polymorphisms in the TNF-α locus are known to be 
related to several autoimmune, infectious such as schistosomiasis and neoplastic diseases 
(Kubota et al., 1998). Several TNF-α SNPs that affect TNF-α gene expression levels such as -
1031 (T/C), -863 (C/A), -857 (C/A), -851 (C/T), -419 (G/C), -376 (G/A), -308 (G/A), -238 
(G/A), -162 (G/A) and -49 (G/A) have been reported (Elahi et al., 2009; Tahan et al., 2016; Tu 
et al., 2018). The -308 SNP directly affect the production of TNF-α. The mutant allele of TNF-
α -308A is associated with high levels of TNF-α; high parasite clearance and severe 
inflammatory conditions (Kubota et al., 1998; Tu et al., 2018).  
1.9. Study Rationale and Justification  
The lack of any one effective treatment, control and/or management option means there is a 
need for concerted efforts aimed at eradication of schistosomiasis. Drug resistance and adverse 
effects of current medicines used to treat and/or prevent schistosomiasis further stress the dire 
need for better options. Given the disease burden patterns, there is need for sub-Saharan 
scientists to participate in the ongoing search for alternative drugs, immunopathology, 
immunoepidemiology and/or anti-schistosomal vaccines.  
The current study is linking the presence of cytokine polymorphisms to susceptibility and 
severity of schistosomiasis as well as to drug outcomes. As highlighted above, other studies 
have linked IL10 to controlling of excessive Th1 and Th2 polarization in granulomatous 
response, and TNFα to both protectiveness and proinflammatory responses. Thus 
polymorphisms on promoter regions of these genes could have strong influence on severity and 
resistance to morbidity of schistosomiasis of children living in endemic areas of Zimbabwe. 
This study helps in further understanding host-parasitic interactions in schistosomiasis and 
helminthiasis in general, protective immunity development and the impact of an individual’s 
immunological profile on disease burden, progression and outcome. This information is 
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essential in informing prevention, immunoepidemiology research and other schistosomiasis 
control strategies.  
The study contributes valuable information on schistosomiasis epidemiology in rural and 
farming communities of Zimbabwe as well as highlight key risk factors (mainly host-genetic 
factors) among children (0-15years). The contributions includes information that will help in 
the optimization of drug therapies. Thus, in summary, this immunogenetic and immuno-
epidemiological study helps with the unravelling of the immuno-epidemiological basis of 
schistosomiasis susceptibility and/or infection as well as other parasitic infections. Apart from 
increasing our understanding on immunogenetics and immuno-epidemiology, this study has a 
positive impact on our parasitic infection treatment, control and prevention strategies as it will 
help in determining prevalence, groups at risk, risk factors (including host genetic factors) and 
effectiveness of previous and present interventions.  
1.10. Study aims and objectives 
1.10.1. Aim 
The main aim of this study is to evaluate frequencies of genetic polymorphism in cytokines IL-
10 and TNF-α gene promoter regions and susceptibility to S. haematobium infections.  
Objective 
To; 
1. Evaluate frequencies of genetic polymorphisms in IL-10 and TNF-α gene promoter 
regions in both S. haematobium infected and unifected children.  
2. Determine genetic predisposition and overall susceptibility to urogenital 
schistosomiasis in children living in endemic areas of Zimbabwe. 
3. Investigate impact of age, gender and location on the prevalence of urogenital 
schistosomiasis in endemic rural and farming communities of Zimbabwe.  
4. Make inferences on the potential impact of single nucleotide polymorphisms of TNF-
 (rs1800629) and IL-10 (rs1800871) on immunological profiles and drug 
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ABSTRACT  
Background: Knowledge gaps exist between host genetic factors and susceptibility to 
schistosomiasis a disease with serious morbidity and pathology.  
Objectives: To determine cytokine levels and single nucleotide polymorphisms of TNF-α 
(rs1800629) and IL-10 (rs1800871) and their possible impact on susceptibility to 
schistosomiasis in pre-school age children. 
Methods: Urogenital schistosomiasis was diagnosed using the urine filtration method, while 
sandwich ELISA was used for cytokine levels determination. The survey was done in August 
of 2015 and reinfection levels post treatment were done at 3, 6 and 12 months. Amplification 
Refractory Mutation System Polymerase Chain Reaction with visualization on 2% agarose gel 
electrophoresis was used for genotyping.  
Results: Urogenital schistosomiasis prevalence was found to be 10.5 % (59/563), where 50.8% 
of children were male and 49.2% were female, and reinfections were detected in only 6 children 
at 3 months and only 1 was reinfected at 12 months. There were no significant differences in 
TNF-α-308 G/A allele or genotype frequencies, respectively, between the S. haematobium 
infected and uninfected participants (p = 0.360 and 0.279). However, no children with the IL-
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10 -819 TT genotype (associated with low production of IL-10) had schistosomiasis. The TNF-
α  GG genotype corresponded with significantly lower TNF-α levels when compared with the 
GA or AA genotypes (p<0.05), and TNF-α levels were significantly lower in infected children 
compared to uninfected children (p<0.05).  
Conclusion: Higher TNF levels and lower IL-10 levels are potentially protective against 
schistosomiasis infection. IL-10 -819 TT genotype is potentially protective against infection 
through its association with lower IL-10 levels. 
Key words: S. haematobium, polymorphisms, cytokines, susceptibility, protective immunity  
 
INTRODUCTION  
Pre-school children from poor and endemic regions like sub-Saharan Africa are at high risk of 
schistosomiasis. The region has poor hygiene and sanitation, conditions that facilitate 
Schistosoma thriving. In the endemic regions people living in both rural and urban centers are 
at risk of getting infected  with schistosomes, as a result of using of open water sources infested 
with intermediate snails harboring the human host infectious stage 1. Most of the people that 
are at risk of schistosomiasis worldwide have low awareness levels of the disease 2,3.  
Urogenital schistosomiasis has been described as a significant public health threat for pre-
school age children (≤5 years); often they have higher infection burdens, and show serious 
morbidity and pathology relative to school-age children 4. Thus pre-school children in endemic 
areas are regarded as a high-risk group and needing inclusion in mass drug administration 
programs 1. Praziquantel treatment despite some few known side effects is acceptable, safe and 
effective in all age ranges; treatment leads to 91% reduction in prevalence as well as 93% 
decrease in infection intensity 4. Praziquantel causes rapid influx of Ca2+ accompanied by an 
intense muscular paralysisis and is known to remove the immune-suppressive effects of adult 
worms as well as lead to expression of worm antigens as a result of dying worm degeneration 
5. Thus praziquantel aids in immunity development.  
Most endemic regions of Zimbabwe has prevalences that range between moderate to high risk 
according to WHO guidelines 6,7. Thus mass praziquantel administration should be done at 
least once every two years 7. Morbidity and mortality of schistosomiasis is well recognized to 
be a consequence of the host immune system 5. People in endemic areas are known to develop 
protective immunity against reinfections, which offers hope for possible vaccines 4. The 
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immunology of schistosomiasis is therefore of great significance in management, control and 
possibly eradication of infection. 
Research, control strategies and treatment guidelines of schistosomiasis in children under 5 
years of age are reported to have lagged behind those in other age groups 5. Thus significant 
knowledge gaps exist for the pre-school age group in relation to prevalence, morbidity, 
mortality, immunology, immunopathology, treatment effectiveness and safety, and impact of 
host genetic factors.  
We therefore assessed cytokine levels as well as cytokine genotypes in pre-school children at 
risk of schistosomiasis. TNF-α and IL-10 have been associated with susceptibility and other 
key immune responses in many diseases including those caused by helminths 8–10. Therefore 
we associated rs1800629 and rs1800871 promoter region polymorphisms, as well as TNF-α 
and IL-10 levels, with susceptibility to urogenital schistosomiasis among pre-school children. 
Reinfection levels post-treatment were also assessed at 3, 6 and 12 months in follow-up 
surveys.  
MATERIALS AND METHODS  
Ethical considerations 
The study was registered and ethically approved by the Zimbabwe’s ethics board for bio-
medical research (the Medical Research Council of Zimbabwe - MRCZ/A/1710). In addition, 
community leaders, Provincial Medical Director and District Medical Officer also granted 
permission to conduct the study in Madziva, Shamva. The children agreed to participate in the 
study and their parents/guardians signed informed consent forms allowing their participation. 
The questionnaires about medical history and informed consent form were translated into 
relevant vernacular languages. The researchers also took time to ensure the guardians or parents 
understood the forms.  The children and parents were educated on the aims, risks and benefits 
of the study. Participation was voluntary and participants were free to withdraw from the study 
at any time.  
Study population and sample  
The study population was previously described Midzi et al (2014) 11. The survey of urogenital 
schistosomiasis prevalence was conducted among 563 children aged between 1 – 5 years 
through collection of urine specimens. Genotyping was done on 268 children who were willing 
and were able to provide adequate blood. Convenience sampling was used, the sample was 
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several times larger than 50 children per centre an estimate made by Midzi et al (2014) 11. The 
children were permanent residents of Madziva area in Shamva district, Mashonaland Central 
province, Zimbabwe. The area was selected for this study based on its high annual rainfall, a 
condition conducive for Schistosome species and leading to high schistosomiasis endemicity 
12. The study was a cross sectional study, which was part of an ongoing longitudinal study on 
urogenital schistosomiasis for the 1-5 age group (see funding section below).  Participants 
infected with S. mansoni as determined by the Katz et al. (1972) 13, were excluded from this 
study. The survey was done in August of 2015 and reinfection levels post treatment were done 
at 3, 6 and 12 months.   
Detection of S. haematobium 
Schistosoma haematobium was diagnosed by the microscopic examination of urine specimens 
for the presence of parasite eggs using the urine filtration technique 14. In brief, urine specimens 
were collected from willing participants for three consecutive days. For diagnosis 10 ml of 
urine was filtered through a nitrile filter membrane. The membrane was stained with iodine 
and examined under a light microscope. The same procedure was repeated on three consecutive 
days in order to prevent misdiagnosis due to day-to-day variation of egg excretion 15. If 
positive, the number of eggs in the entire sample of 10 ml of urine was counted and recorded 
as light infection if 1 - 10, moderate infection if 11 - 49 or heavy infection if > 50 eggs. 
Participants who were S. haematobium positive were treated with a single dose of praziquantel 
(40 mg per kilogram of body weight). Bread and orange juice were given as supplementary 
food in order to enhance absorption as well as to alleviate the nauseating effects of praziquantel. 
Stool samples were collected once for S. mansoni diagnosis. Urine collection procedures and 
the diagnosis were repeated at 3, 6 and 12 months to assess reinfection levels post treatment 
with praziquantel.   
Blood collection 
Approximately 5 ml blood was collected into Ethylenediamine tetraacetic acid (EDTA) tubes. 
The tubes were centrifuged at 3000 rpm for 10 minutes using a rotofix centrifuge.  Plasma was 
collected and used to measure the levels of systemic cytokines.  Host DNA was extracted from 
whole blood for genotyping using the Qiagen FlexiGene DNA extraction kit (Qiagen 





The TNF (rs18006290) and IL10 -819T>C (rs1800871) polymorphisms were determined using 
amplification refractory mutation system-polymerase chain reaction (ARMS-PCR). The 
primers used were from Inqaba Biotechnology, Pretoria, South Africa (Table 1). Primers 
specific for wild type genotype (1ul) and mutant genotype (1ul) were separately mixed with 
1ul (10 mM) generic primer, 0.5 ul 10 mM forward and 0.5 ul 10 mM reverse internal control 
primers (human growth hormone), 12.5 ul quick load Taq 2x master mix (New England 
Biolabs, Ipswich, MA USA 01938-2732) and 4.5 ul of sterile, nuclease-free water (New 
England Biolabs). Five microliters of the template DNA was added to the master mixes and 
loaded onto a thermocycler (PXE 0.2 thermocycler Thermo Electron Corporation, Waltham, 
MA USA 02451). IL-10 -819 T>C alleles were amplified using the following conditions: 1 
minute denaturation step at 95°C; 10 cycles of 15 seconds at 95 °C, 50 seconds at 65 °C, and 
40 seconds at 72 °C; and 20 cycles of 20 seconds at 95 °C, 50 seconds at 59 °C and 30 seconds 
at 72 °C, followed by cooling at 4 °C. TNF polymorphisms were amplified using the following 
conditions: 1 minute denaturation step at 95°C; 10 cycles of 15 seconds at 95 °C, 45 seconds 
at 60 °C, and 35 seconds at 72 °C; 25 cycles of 20 seconds at 95 °C, 45 seconds at 60 °C, and 
45 seconds at 72 °C, followed by cooling at 4 °C. ARMS-PCR amplicons were analysed by 
electrophoresis on 2 % agarose gel stained with ethidium bromide. The gels were viewed on a 
UV trans-illuminator to score the presence or absence of the cytokine gene polymorphisms.  
TNF- and IL-10 determination 
The levels of the cytokines were measured by indirect enzyme linked immunosorbent assay 
(ELISA) using MABTECH, 3510-1H-6 kits, according to the manufacturer’s instruction 
(Mabtech AB, Büro Deutschland, Germany).  The assay was performed in duplicate and the 
data was averaged.  
Statistical analysis 
Genotype frequencies of the TNF (rs1800629) and IL-10 -819T>C (rs1800871) between S. 
haematobium infected and uninfected participants were compared by Chi-square test. The 
Hardy-Weinberg equilibrium was assessed for TNF (rs1800629) and IL-10 -819T>C 
(rs1800871) S. haematobium infected and uninfected participants groups by Chi-square. 
Genotype data was analysed with the software IBM SPSS Statistics for Windows, Version 
19.0. (IBM Corp., Armonk, NY, USA). Cytokine levels were compared between infected and 
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uninfected participants using unpaired t-tests, and between different genotypes and ANOVA 
was used to compare between light, moderate and heavy infection groups. P-values < 0.05 were 
considered statistically significant.  
RESULTS 
Prevalence of S. haematobium infection 
There was no significant difference (p = 0.823) between boys (n = 294) and girls (n = 269) 
recruited. The prevalence of S. haematobium was 10.5 % (n=59/563), with an even distribution 
between males (50.8 %) and females (49.2 %) (p = 0.82).  
Table 1: List of primers used in genotyping 
Cytokine Position Mutation Primer sequence (5’-3’) Fragment  
rs1800871 -819 C→T Wild type: CCC TTG TAC AGG TGA TGT 
AAC 
Mutant:  CCC TTG TAC AGG TGA TGT 
AAT 
Generic: AGG ATG TGT TCC AGG CTC 
CT 
233 bp 
rs1800629 -308 G→A Wild type: AGG TTT TGA GGG GCA TGG 
Mutant:     AGG TTT TGA GGG GCA TGA 




TNF and IL-10 genotypes are not associated with infection status or intensity  
All genotypes of rs1800629 and rs1800871 were represented in the population, and consistent 
with previous literature, the TNF-α-308 GA genotype and IL-10 CT genotype were the most 
common.  None of the genotypes studied showed significant differences between the infected 
and uninfected groups (Table 2). When stratified the data by infection intensities again there 
no significant differences between the infected and uninfected groups. (Table 3). Interestingly, 
10 children had the IL-10 TT genotype (associated with low production of IL-10) and none of 
these were infected, raising the hypothesis that the TT genotype might be protective against S. 
haematobium, although this was not statistically significant. 
It was found that the rs1800871 single nucleotide polymorphism (SNP) was in line with the 
Hardy-Weinberg equilibrium in uninfected participants (Table 2).  However the rs1800629 
SNP was not in line with Hardy-Weinberg equilibrium in both S. haematobium infected and 
uninfected participants (Table 2). 
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Table 2: Genotype distributions of TNF (rs1800629) and IL-10 -819T>C (rs1800871) 
between S. haematobium infected and uninfected groups. 
 












rs1800629   2.276 0.320 1595.664 0.000 70.311 0.000 
GG 21 (8.7) 3 (12.5)  
AG 158 (65,3) 18 (75) 
AA 63 (26.0) 3 (12.5) 
rs1800871   0.951 0.622 6.781 0.034 _ _ 
CC 12 (24.5) 2 (40.0)  
CT 32 (65.3) 3 (60.0) 














Table 3: Genotype distributions of TNF (rs1800629) and IL-10 -819T>C (rs1800871) 












rs1800629     2.847 0.828 
GG 21 (8.7) 2 (11.8) 1 (16.7) 0 (0)  
AG 158 
(65.3) 
13 (76.5) 4 (66.7) 1 (100) 
AA 63 (26.0) 2 (11.8) 1 (16.7) 0 (00 
rs1800871     1.131 0.889 
CC 12 (24.5) 1 (33.3) 1 (50) 0 (0)   
CT 32 (65.3) 2 (66.7) 1 (50) 0 (0)   
TT 5 (10.2) 0 (0) 0 (0) 0 (00   
 
 
Cytokine levels were associated with cytokine genotypes and infection    
The TNF-α  GG genotype corresponded with significantly lower TNF-α levels when compared 
with the GA or AA genotypes (Figure 1 a) (p<0.05), and TNF levels were significantly lower 
in infected children compared to uninfected children (Figure 1 b). The IL-10 TT genotype 
corresponded with significantly lower IL-10 levels when compared with CC (Figure 1 c). IL-
10 levels were significantly lower in uninfected children compared to infected children (Figure 













































































Figure 1: Genotypes, cytokine levels and infection status 
a - Genotypes and TNF-α production (mean level for AA is 179.3 ± 31.2 pg/ml n=34, GA is 
176.8 ± 23.8 pg/ml n=98 and GG is 131.6 ± 36 pg/ml n=14); b - TNF-α levels against infection 
intensity (239 ± 71.6 pg/ml n=23 and 210 ± 17.6 pg/ml n=286); c - Genotypes against IL-10 
plasma levels (CC - 528.5 pg/ml, CT - 323.8 pg/ml  and TT – 309.4 pg/ml) d - IL-10 plasma 







Reinfections at 3 months post-treatment were detected in 10.2% (6/59) of children that were 
previously infected.  At 6 months there were no-reinfections observed and only one child was 
reinfected after one year post-treatment.  
DISCUSSION  
The study describes results from a survey on prevalence of urogenital schistosomiasis in 
preschool children and impact of single nucleotide polymorphisms of TNF-α-308 G/A and IL-
10-819 C/T gene promoter regions on cytokine levels, susceptibility to S. haematobium 
infections and treatment outcomes. The results highlighted and supported existing evidence on 
schistosomiasis prevalence levels (10.5%) in 1-5 years old males and females and also 
supported the possible effectiveness in mass drug administrations and immune development 
facilitation effects of praziquantel treatment as only 6 were reinfected by 1 year post-treatment. 
The study showed that cytokine levels were different depending on the individual’s genotype:  
the IL-10 -819 CC genotype corresponded with the highest levels of IL-10, while the CT and 
TT genotypes corresponded with moderate and low levels of IL-10, respectively; and the TNF-
α-308 AA genotype corresponded with the highest, GA with moderate to high and GG with 
low TNF-α levels. A major finding was that TNF-α and IL-10 levels predict susceptibility to 
S. haematobium infection, with higher TNF-α and lower IL-10 levels conferring protection. 
Interestingly, all 10 children who had the IL-10 TT genotype (associated with low production 
of IL-10) were uninfected, suggesting that this genotype may confer a protective effect, 
although this was not supported by statistical tests. Higher levels of IL-10 have also previously 
been linked with possible S. haematobium susceptibility 16. IL-10 has immunomodulatory 
effects which may explain the susceptibility to schistosome infections - higher levels of IL-10 
have also been demonstrated to be protective against serious morbidity 16,17. Higher levels of 
the pro-inflammatory cytokine (TNF-α) could aid in immunity development against 
schistosomes as is suggested by the findings of this study. Also the findings of the present study 
show that intensity of infection was somewhat linked to TNF-α levels as those with moderate 
levels of TNF-α had light infection (1-10eggs/10ml of urine) and those with low levels had 
moderate infection (11-49eggs/10ml), although this was not statistically significant?. This 
supports the hypothesis that TNF-α is also helpful in limiting the proliferation of the parasite.  
The allele or genotype frequencies were as expected in Africans - IL-10 819 CT genotype 
frequencies were above 50% and TNF-α-308 GA genotype frequencies were above 80% 18,19. 
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The relationship between cytokine levels and genotypes was also consistent with that in 
previous studies 20. IL-10 -819 CC genotype corresponded to high levels of plasma IL-10 while 
CT to moderate and TT to low levels of IL-10 levels. For TNF-α-308 AA genotype 
corresponding to high, GA – moderate to high and GG – low plasma levels of TNF-α 20. IL-10 
promoter SNPs -1082G/A, -819C/T and -592C/A, are involved in differential IL-10 gene 
transcription and hence differential IL-10 production 20. The findings highlighted a general lack 
of association between any genotype with urogenital schistosomiasis however the data pointed 
to a possible protective effect of IL-10 -819 TT. Given that actual cytokine levels, rather than 
the SNPs studied here, show an association with susceptibility to S. haematobium infection, 
the findings highlight complexities that may exists in the expression of those genes and/or that 
additional SNPs play an important role in the expression of these cytokines. Although no 
clearly significant association was demonstrated in this study, IL-10 haplotypes GCC and GTA 
were previously linked to high/moderate IL-10 production were demonstrated to be associated 
with schistosomiasis 20. This may highlight the need for a larger sample size to demonstrate the 
suggested link between genotypes and susceptibility or the need to identify and study other 
polymorphisms that affect expression of IL-10 and TNF-α.  
Peripheral blood mononuclear cells from subjects with schistosomiasis have been shown to 
produced 8 fold greater levels of egg antigen–driven TNF-α leading to a 99 fold greater mean 
TNF-α : IL-10 ratio, relative to negative controls 17. Some studies have established a positive 
relationship between infection intensity and TNF-α production 21,22. IL-10 elevation in 
schistosome infections was also demonstrated with some authors suggesting both TNF-α and 
IL-10 as a possible biomarkers in schistosomiasis 21–23. Thus the high levels of IL-10 in infected 
individuals could have been a result of the infection rather than the cause of infection.  
However, there are previous reports that high levels of IL-10 predispose to reinfection 8–10 and 
we found that no individuals with the IL-10 TT genotype (which was also associated with lower 
IL-10 levels) were infected.  Taken together these observations support that the association 
between IL-10 levels and schistosomiasis in our study is due to higher IL-10 levels 
predisposing to infection and lower levels conferring protection. Some studies detected 
elevated levels of TNF-α in infected individuals relative to uninfected controls especially in 
acute schistosomiasis 24.  The findings of this study however contradicts those observations as 
low levels of TNF-α were associated with infection, which actually support the inferences that 




In this study most children did not get re-infected after 3, 6 and 12 months suggesting possible 
efficacy of praziquantel mass drug administrations in elimination of schistosomiasis efforts. 
The few that got possible reinfection fall in the category of moderate to high production of 
TNF-α (individuals with the TNF-α GA and AA genotypes), which appears contradictory to 
our observation that high levels of TNF-α are negatively associated with infection. The effects 
of praziquantel treatment on immunological profiles and immunity to reinfection was reported 
to be similar in all age groups of children 4. However, TNF-α was shown to play a complex 
role in propagating the intramammalian stages of the schistosome life cycle - an effect that 
helps schistosome survive in the host 25. This might explain the observed few reinfections.  
Alternatively some of the “reinfections” might represent treatment failure cases, particularly 
since 5/6 cases were observed at 3 months post-treatment, and high levels of TNF-α may have 
predisposed the individuals to treatment failure. Some studies suggest that IL-10 blocks the 
development of immunity after praziquantel treatment thus re-infection is better prevented 
when praziquantel treatment is administered in individuals with low or blocked IL-10 26. Some 
researchers have reported contradictory findings for example intermittent treatment of S. 
japonicum or S. mansoni infection has been shown to increase the risk for respective disease 
in some individuals 17. The re-infections could also be explained by the fact that the participants 
were inhabitants of an endemic areas and praziquantel administrations were not coupled with 
other key interventions like killing of intermediate hosts and provision of safe water. Thus the 
study could not conclusively explain the re-infections. The significant reduction of prevalence 
over the 12 months could help support sustained community based praziquantel 
administrations. Such efforts can be reasonably expected to significantly reduce the 
schistosome burdens in endemic areas.   
The prevalence of 10.5% though still high may suggest effectiveness of prior mass drug 
administration and health education efforts as it is below 20.8% (nationally reported urogenital 
schistosomiasis prevalence in 2012) 27. In 2011, the province (Mashonaland Central) had 
overall prevalence of 26.1 (23.46–28.90) and Shamva was also categorized among the top 
districts with heavy intensities (53.2%) of S. haematobium infections 12. More efforts like snail 
control, preventative chemotherapy and improvement of hygiene and sanitation are still 
required as these have at some point sustained prevalence below 10% in areas like Hippo 
Valley Sugar Estates, Zimbabwe 28. The observed lack of differences in prevalence of 
schistosomiasis in males and females is in contrast to what was established by major surveys 
conducted in Zimbabwe previously 12,29. In those primary school surveys females consistently 
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had lower prevalence of infection compared to their male counterparts. The lack of differences 
between boys and girls can be attributed to many often overlapping activities or chores like 
swimming, washing and fetching water from unprotected sources. The major factor is also that 
the water contact of pre-school children is parent or guardian related, thus no differences could 
be expected. Gender differences in activities often starts to vary at around age 6 thus similar 
prevalence of infection is expected in children <6 years of age and gender differences may 
emerge thereafter  30.  
Limitations  
The prevalence of schistosomiasis was low which could have limited the ability to highlight 
association of any of the studied genotypes with susceptibility to S. haematobium. Those the 
sample was larger than the recommended 50 participants per centre resources limited the ability 
to have more participants which could have helped in establishing rare phenomena. The results 
could also have been affected by the fact that we had a few individuals who had heavy infection 
intensities. Also better results on possible association of urogenital schistosomiasis and 
genotypes could have been obtained if all the recruited children were willing and able to 
provide adequate blood for genotyping. The highlighted limitations could be managed by 
combining the genotyping data with other similar data from children even of another age group 
and analyse for possible associations. Future studies are recommended to include many 
cytokines and all possible single nucleotide polymorphisms known to influence cytokine gene 
expression.  
CONCLUSION  
Prevalence of urogenital schistosomiasis among boys and girls was indistinguishable 
statistically. For TNF-α-308 GA genotype had the highest frequency and AA, GA and GG 
genotypes were associated with high, moderate to high and low production of TNF-α. TNF-α 
-308 G/A and IL-10 -819 C/T polymorphisms were not significantly associated with 
susceptibility to S. haematobium infection, although no individuals with the IL-10 TT genotype 
(n=10), which is associated with lower IL-10 levels were infected in this study. Higher TNF-α 
and lower IL-10 levels were negatively associated with infection and are suggested to confer 
protection against schistosomiasis. Praziquantel helped in significantly reduce prevalence of 
schistosomiasis in pre-school children staying in an endemic area.  
The obvious implications of the findings include the need for continued efforts (mass drug 
administrations, better sanitation and hygiene and health education and promotion) to reduce 
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prevalence to zero among children in endemic areas of Zimbabwe. Other implications could 
include immune-based interventions that encourage TNF-α but limit IL-10 production as this 
will promote immunity against S. haematobium, with possible risks associated with the 
resultant proinflammatory environment. 
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CHAPTER 4  
Additional findings: Risk factors of schistosomiasis in selected endemic areas of rural 
Zimbabwe 
4.1. Summary of the study population in total  
The following results are from additional analysis of combined data for both preschool (1 – 5 
years) and primary school (6 – 15 years) children. The data analysed was generated as outlined 
in chapter 2 and 3 methodology sections. Table 4.1 shows the summary of the total population 
after combining all the children (preschool and school age children).  
4.2. Statistical analysis 
Genotype frequencies of the TNF (rs1800629), IL-10 -819T>C (rs1800871) and IL-10 -
1082A>G (rs180096), between S. haematobium infected and uninfected participants were 
compared by Chi-square test. The Hardy-Weinberg equilibrium was assessed for TNF 
(rs1800629), IL-10 -819T>C (rs1800871) and IL-10 -1082A>G (rs180096), S. haematobium 
infected and uninfected participants groups by Chi-square. Genotype data was analysed with 
the software IBM SPSS Statistics for Windows, Version 19.0. (IBM Corp., Armonk, NY, 
USA). Where it was not possible to determine the Hardy-Weinberg equilibrium using SPSS 
equations shown below were used for the assessment. P-values < 0.05 were considered 
statistically significant. 
= ( − )  
= ( − 1)( − 1) 
                                                         Where X2 = Chi square 
                                                                              df= degrees of freedom  
                                                                              r= number of columns 
                                                                              c= number of raws 
                                                                              O= observed value  
                                                                                  E= expected value 




A total of 924 participants, 485 (52.5 %) males and 439 (47.5 %) females and 354 (38.3 %) 
primary school aged children and 570 (61.7 %) pre-school aged children were recruited for the 
study. The demographic of 158 (17.1 %) S. haematobium infected participants and 766 (82.9 
%) uninfected participants are shown in Table 4.1. No significant difference was found between 
the S. haematobium infected and uninfected groups in terms of gender (x2=0.114, p=0.735). 
Significant difference was found between S. haematobium infected and uninfected groups in 
terms of study site (x2=38.943, p=0.000) and age group (x2=38.377, p=0.000). The older the 
child the higher the risk of getting infected by S. haematobium (10.5% in 0-5 year olds; 24.0% 
in 6-10 year olds and 30.7% in 11-15 year olds; p = 0.000). 
Table 4.1: Demographic and clinical characteristics of S. haematobium infected and 
uninfected individuals in the total study population 
Variable Uninfected Infected X2 P value 
Site   38.943 0.000 
Bemberi 86 (11.2) 35 (22.2)  
Bandanyenje 173 (22.6) 60 (38.0) 
Madziwa 507 (66.2) 63 (39.9) 
Gender   0.114 0.735 
Male 404 (52.7) 81 (51.3)  
Female 362 (47.3) 77 (48.7) 
Age group   38.377 0.000 
Primary school aged children 
(6-13) 
259 (33.8) 95 (60.1)  








We observed that the GG, AG, and AA genotypes of TNF (rs1800629) showed significant 
differences between S. haematobium infected and uninfected groups (x2=26.089, P=0.000; 
table 2) and the CC, CA genotypes of IL-10 -819T>C (rs1800871) and IL-10 -1082 A>G 
(rs1800896) revealed no significant differences between the infected and uninfected groups 
with p-values of 0.092 and 0.559 respectively. However, we found all the SNPs TNF 
(rs1800629), IL-10 -819T>C (rs1800871) and IL-10 -1082 A>G (rs1800896) were not in line 
with Hardy-Weinberg equilibrium in both the infected and uninfected groups. 
 
Table 4.2: Genotype distributions of TNF (rs1800629), IL-10 -819T>C (rs1800871) and 
IL-10 -1082 A>G (rs1800896) between S. haematobium infected and uninfected groups 
 
SNPS Uninfected Infected X2 P 
value 
Uninfected Infected 
X2 for HWE P value for 
HWE 
X2 for HWE P value for 
HWE 
rs1800629   26.089 0.000 992.787 0.000 741.804 0.000 
GG 151 (34.1) 49 (51.6)  
AG 225 (50.8) 41 (43.2) 
AA 67 (15.1) 5 (5.3) 
rs1800871   4.776 0.092 38.239 0.000 20.814 0.000 
CC 69 (27.5) 14 (18.7)  
CT 163 (64.9) 55 (73.3) 
TT 19 (7.6) 6 (8.0) 
rs1800896   0.342 0.559 383.52 0.000 536.68 0.000 
GG 9 (4.5) 2 (2.9)  
GA 193 (95.5) 68 (97.0) 





4.4. Discussion  
The findings highlight that while age and geographical location were risk factors to 
schistosomiasis gender was not. The average prevalence of schistosomiasis among the study 
participants was 17.1 % (158/924). Based on the global distribution map (Figure 4.1) of 2012, 
Zimbabwe is in the moderate range for schistosomiasis infection (10 – 49% prevalence) 
(ECDC, 2014). Thus, the findings of this study not only support the categorization but also 
help highlight the strong need for more concerted efforts in the fight against schistosomiasis.  
 
Source: http://gamapserver.who.int/mapLibrary/Files/Maps/Schistosomiasis_2012.png 
Figure 4.1: Global distribution of schistosomiasis  
In endemic areas almost every one of the long-term residents will be infected with schistosomes 
at some point in their life. In regions with typical transmission patterns school going children 
carry 60 – 80% of the infection burden as compared to adults (Colley et al., 2014). Children 
are at risk of schistosomiasis due to many activities that brings the in contact with open water 
sources such as dams and rivers and their immature immunological status (Chisango et al., 
2019). Age, gender, occupation, female household head's education level, religion, 
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socioeconomic status, agricultural activities, water sources and house location are some of the 
factors that have been found to influence a person's contact with infested water (Yang et al., 
2009; Colley et al., 2014; Chadeka et al., 2017; Mewabo et al., 2017; Hajissa et al., 2018). 
Studies in Nigeria also highlighted swimming and drinking contaminated water as the most 
important risk factors followed by washing clothes and taking baths in rivers (Oluwasogo and 
Fagbemi, 2013). A study in Kano State, Nigeria suggested history of S. mansoni and S. 
haematobium infection and presence of infected family members as key risk factors of 
schistosomiasis (Dawaki et al., 2016). This can be explained by sustained presence of the 
parasite in common water sources. Some studies have highlighted that it is actually the 
frequencies of water contact (taking baths, swimming, and wading in possibly infested streams) 
that is associated with higher schistosomiasis prevalence (Ismail et al., 2014; Abdulkareem et 
al., 2018).  Other risk factors identified in literature include lack of portable drinking water, 
unemployment and lack of knowledge about schistosomiasis (Abdulkareem et al., 2018). 
The insignificant variation (p=0.735) between boys (16.7%) and girls (17.5%) could be as a 
result of similar water contact patterns between boys and girls despite disparities in recreational 
activities like swimming and chores like fetching water from and laundering in rivers 
characterizing most of the Zimbabwean rural societies. The findings also dispels myths that 
males have higher schistosomiasis prevalences relative to women (Bruun and Aagaard-Hansen, 
2008). Instead women tend to have higher prevalence due to social and occupational roles. 
Social and occupational roles influence exposure patterns and perceptions of illness 
(haematuria is sometimes confused with menstrual periods and women are sometimes forced 
to ignore symptoms) often leaves females with the greater burden of schistosomiasis; 
knowledge of those disparities as well as exact prevalences in both genders is key in coming 
up with effective schistosomiasis control programmes (Bruun and Aagaard-Hansen, 2008). 
Differences in exposure, vulnerability, access to treatment and health outcomes that exist 
between men and women have been recognized in many communities. This is also explainable 
by the fact that most women and girls in many low to middle income communities with 
schistosomiasis are in the low socioeconomic class (Feasey et al., 2010). Studies in Igbokuta 
Village, Nigeria reported higher prevalence in girls (61%) relative to boys (39%) (Oluwasogo 
and Fagbemi, 2013). Other studies such as the one done in Kaduna state, Nigeria have however 
highlighted higher prevalence in boys 14.8% than girls (5.4%) (Bishop and Akoh, 2018). This 
shows how schistosomiasis prevalence is sensitive to social and occupational activities 
(swimming, washing and irrigation farming) variations that occurs from region to region 
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depending on people’s cultures and/or religions. In urban centres it has been highlighted that 
boys could be 7.8 times more likely to be infected with schistosomes than girls (M’Bra et al., 
2018). This is more likely due to the fact that young boys in urban centres are the only group 
that have outdoor activities that may lead contact with water such as swimming in ponds and 
other open water bodies. 
Agricultural and fishing activities as well as lack of basic infrastructure in many communities 
are among key factors bringing people in contact with possibly contaminated water (Yang et 
al., 2009; Mewabo et al., 2017; Abdulkareem et al., 2018; Hajissa et al., 2018); often school 
going children are central in many agricultural activities in rural Zimbabwe.  Kabuyaya et al, 
(2017) reported that school going children from households headed by women were at a higher 
risk to be infected by S. haematobium relative to those with both parents. Women headed 
households often rely more on children for regular chores like washing and fetching water 
(Kabuyaya et al., 2017). Poor people often have poor access to safe water and sanitation as 
well as low levels of knowledge. Thus schistosomiasis prevalence is generally highest amongst 
the poorest regions in endemic countries (Bruun and Aagaard-Hansen, 2008). A study done in 
northern Côte d’Ivoire however contradicted the link between socioeconomic status and 
schistosomiasis prevalence (M’Bra et al., 2018), further highlighting the complexities in 
schistosomiasis epidemiology. Thus there is a continuing need for more immuno-
epidemiological studies as strategies to eliminate schistosomiasis are both being formulated 
and implemented (for monitoring and evaluation).   
The study has demonstrated that age is a factor; the older the child the higher the prevalence 
(10.5%, 24.0% and 30.7% for 1-5, 6-10 and  11-15 years respectively). Some studies have also 
have also highlighted similar findings. Children between 10 and 15 years of age are 3.8 times 
more likely to be infected than their younger counterparts aged 5-10 years, who are in turn 
more likely to be infected than pre-school aged children (M’Bra et al., 2018). Children 5 years 
and under typically have very low to nil prevalence depending on region and social fabrics; 
they are often too young to engage in many regular activities that brings them in contact with 
schistosome infested waters (Bishop and Akoh, 2018).   
A long history (1967 to 2001) of focal mollusciciding using niclosamide as well as systematic 
screening and treatment of all residents in the Zimbabwean side of Kariba dam has been used 
to explain lower prevalence observed in this region when compared to the Zambian side where 
no such programs exist (Chimbari, 2012). Many other examples in Zimbabwe, such as the 
67 
 
Hippo Valley Sugar Estates and Mushandike schistosomiasis control programmes, also 
highlight that sustained multifaceted control programmes significantly lead to reduction in 
prevalence and morbidity (Chimbari, 2012). The World Health Assembly in May of 2012 
announced the feasibility of schistosomiasis eradication and encouraged water, sanitation and 
hygiene education (WASH) as components of an integrated control and elimination strategy 
(Grimes et al., 2015). Praziquantel mass drug administrations and WASH programmes (Table 
4.5) help in reducing environmental contamination with schistosome eggs as well as people 
coming in contact with contaminated water bodies. Washing with soap also helps as soap is 
known to be toxic to cercariae, miracidia and some freshwater snails (Grimes et al., 2015).  
Table 4.3: WASH components key in schistosome transmission control (Grimes et al., 
2015) 
Domain Key points  
Water  Safe water supplies help in reducing exposure. 
 Infrastructure such as sinks and showers limit contaminated water contact.  
Sanitation   Eggs in latrine pits or proper sewer lines cannot sustain schistosome 
transmission.  
Hygiene  Soap is toxic to miracidia, cercariae and intermediate host snails 
 
Mass drug administration of praziquantel, WASH, health education and community 
mobilizations are imperative in the fight against schistosomiasis (Dawaki et al., 2016). Control 
of the intermediate host snails (Bulinus globosus and Biomphalaria pfeifferi) is also central to 
enhance the effectiveness of the treatment based approach (community praziquantel mass drug 
administrations) (Chimbari, 2012). Studies also suggested that for effectiveness, educating 
communities about schistosomiasis should be an integral part of all mass drug administration 
campaigns (Chisango et al., 2019). Continuous evaluation of all possible risk factors is 
essential if schistosomiasis is going to be eliminated from endemic communities or if a 
significant positive impact is to be made in its control.  
4.5. Conclusion  
Age and location are important factors in determining schistosomiasis morbidity or prevalence. 




4.6. Recommendations  
 There is need for regular epidemiological surveys to both inform policies and strategies in 
combating schistosomiasis as well as guide monitoring and evaluation of implemented 
programmes.  
 Regular assessment of all possible risk factors including those that could be dynamic and/or 
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SYNTHESIS OF RESEARCH FINDINGS AND CONCLUSIONS 
5.1. Synthesis of research findings  
This thesis reports on the project that was conducted to answer the overall objective of 
evaluating frequencies of genetic polymorphisms in TNF-α and IL-10 cytokine gene promoter 
regions in Zimbabwe. The regions are known to influence serum cytokine balance that is key 
in determining the morbidity and pathological consequences in many helminthic infections 
such as S. haematobium infections. The proinflammatory cytokine (TNF-α) and anti-
inflammatory (IL-10) are thought to determine susceptibility to S. haematobium. The study 
was also aimed at making inferences on the potential impact of those single nucleotide 
polymorphisms (SNPs) on immunological profiles and drug administration outcomes.  The 
studies presented in this thesis showed that the overall prevalence of urogenital schistosomiasis 
among the children surveyed was 17.1% and gender specific prevalence was indistinguishable 
statistically (17.5% in girls and 16.7% in boys; p = 0.735). Age group specific findings 
highlighted significant difference in prevalence between primary school children (26.8%) and 
preschool children (10.5%). Praziquantel treatment reduced prevalence among the study 
participants as reinfections were only recorded in few children (6/59; 10.2% of previously 
infected children). Praziquantel treatment has been demonstrated to markedly alter polarization 
of schistosome-specific cytokine responses, and those changes, particularly in response to egg-
stage parasites, are thought to promote resistance to reinfection (Bourke et al., 2013). Thus the 
noted significant decline in prevalence and very low rates of reinfection following praziquantel 
treatment could be attributed to the said effects. There is however need to correct for other 
known effective interventions like health information about S. haematobium given to children 
and guardians.  
Allele or genotype frequencies and the resultant cytokine levels were as expected among 
African children; with the TNF-α-308 GA and IL-10-819 CT genotypes having the highest 
frequency. The TNF-α AA, GA and GG genotypes were associated with high, moderate to high 
and low production of TNF-α, respectively. This is consistent with a previous study showing 
bi-allelic single nucleotide substitution of G (TNFA1 allele) with A (TNFA2 allele) 
polymorphism at −308 nucleotides upstream from the transcription initiation site in the TNF-
α promoter is associated with elevated TNF-α levels (Elahi et al., 2009). The IL-10 TT 
genotype corresponded with significantly lower IL-10 levels when compared with CC (which 
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had highest levels) and CT genotypes. The impact of SNPs in IL-10 promoter region on 
circulating levels of the cytokine is also consistent with findings from other studies (Makwikwi 
and Mduluza, 2019). TNF-α -308 G/A and IL-10 -819 C/T polymorphisms studied here were 
not associated with susceptibility to S. haematobium infection as the distribution of genotype 
frequencies did not differ significantly between the infected and uninfected participants. Higher 
TNF-α and lower IL-10 levels were negatively associated with schistosomiasis. Although cause 
and effect could not be determined, previous reports that high levels of IL-10 predispose to 
reinfection (Baran et al., 2008; Sun et al., 2010; Santos et al., 2017) our observation that no 
individuals with the IL-10 TT genotype (which was also associated with lower IL-10 levels) 
were infected, support that lower levels of IL-10 confer protection against schistosomiasis 
infection. Despite the association between cytokine levels and schistosomiasis and the expected 
association between the various genotypes and cytokine levels, the genotypes did not 
individually significantly associate with susceptibility to infection. The findings therefore 
further highlight the complexities in immunity and host-parasite interactions. Nevertheless, 
since the genotypes are independent variables, chances of matching exact genotypes that will 
have low TNF-α and high IL-10, hence conferring increased susceptibility to S. haematobium 
infection, are low. In addition the impact of individual genotypes will probably be more marked 
if corrections for other known risk factors were instituted.  
As highlighted above this present study has established that high serum levels of IL-10 and low 
TNF-α as positively linked with S. haematobium infection, and while cause and effect in this 
relationship was not proved in this study, it can be inferred from observations in the present 
study as well as previous studies. IL-10 is a potent anti-inflammatory cytokine produced by 
lymphocytes (Njaanake et al., 2014). One study reported IL-10 elevation in chronic helminth 
infection (Arinola et al., 2015) thus the susceptibility noted could potentially be a result of 
chronic infection and not as a result of IL-10 being a risk factor, however other studies have 
reported no elevation of IL-10 after S. haematobium infection (Lo et al., 2018). Furthermore, 
other studies with IL-10 being reported to be a risk factor of S. haematobium 
infection/reinfection after adjusting for other variables (Van Den Biggelaar et al., 2002; 
Bustinduy et al., 2015; Elfaki et al., 2016).  These studies, together with our observation that 
no individuals with the IL-10 TT genotype (corresponding with low IL-10 levels) were infected 
support that low IL-10 is protective against infection and that high IL-10 is a risk factor for 
infection. Single nucleotide polymorphism in the promoter regions of IL-10 have also been 
associated with many disease such as psoriasis, gastric cancer and dengue (Baran et al., 2008; 
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Sun et al., 2010; Santos et al., 2017). This study has also linked higher TNF-α serum levels to 
protection against S. haematobium infection. Most studies however have failed to establish any 
link between TNF-α serum levels and S. haematobium infection but rather to serious 
pathological developments in chronic infection (Bustinduy et al., 2015). TNF-α has been 
implicated in the pathogenesis of many diseases and in influencing disease susceptibilities 
(Elahi et al., 2009). Some studies detected elevated levels of TNF-α in infected individuals 
relative to uninfected controls especially in acute schistosomiasis (Coutinho et al. 2006).  The 
findings of this study however contradicts those observations as low levels of TNF-α were 
associated with infection, which actually support the inferences that higher levels TNF-α are 
actually protective against S. haematobium. 
Praziquantel has a significant role in the elimination of schistosomiasis or at least in significant 
reduction of schistosome burden with in endemic communities. The MDA that associated with 
the study led to fewer and fewer reinfections. Significant reduction in prevalence a year after 
treatment with praziquantel was also reported by a study done in central Sudan, highlighting 
the central role praziquantel has in any schistosomiasis elimination programme (Ahmed et al., 
2012). Similar findings were reported as well by Chisango et al (2019); in their study 
praziquantel did not only led to significant reduction of prevalence but infection intensities as 
well (Chisango et al., 2019). This was based on egg reduction rates cure rates after single or 
divided 40mg/kg dose(s) of praziquantel. The egg reduction rates ranged between 80 to 100% 
(Taylor, 2008; Ojurongbe et al., 2014; Chisango et al., 2019).  As highlighted above the 
effectiveness of this significant reduction in prevalence after treatment could also be attributed 
to the knowledge and/or information about schistosomiasis given to the children and guardians 
on every encounter. The few reinfections however points to the fact that praziquantel cannot 
be used alone but for significant and sustained effectiveness it should be combined with other 
known effective strategies such as WASH (water, sanitation and hygiene), snail control and 
health education. Mduluza et al. (2001) reported significant reduction in prevalence and 
infection intensities of S. haematobium when praziquantel was given every 8 months for 2 
years in children under 6 years living in endemic areas. They also noted a shift in antibody 
profiles towards protective antibodies (IgA and IgG1) further highlighting the impact of 
praziquantel in schistosomiasis eradication (Mduluza et al., 2001; Chisango et al., 2019).   
Mass drug administration (MDA) programs that include pre-school and school going children 
as well as adults have been found to be cost-effective based on the incremental cost 
effectiveness ratio (ICER) per disability-adjusted life-year (DALY) averted (ICER $167 per 
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DALY averted), in a study done in Côte d’Ivoire (Lo et al., 2015). Repeated school based MDA 
programmes have many incremental and additional (externalities) benefits such as Quality-
Adjusted Life-Years (QALYs) gained, rapid reduction of prevalence and infection intensity, 
increased coverage and infection interruption despite seemingly increasing costs (King et al., 
2011). Externalities include enhanced HIV and other STI prevention strategies; depending on 
HIV prevalence in any given region, treatment of schistosomiasis has been linked to decreased 
transmission of HIV (Ndeffo Mbah, Gilbert and Galvani, 2014). Thus sustained and frequent 
community-wide MDA programmes, multi-sectorial approaches and community participation, 
provision of clean water, sanitation and health education are recommended even in 
communities with low schistosomiasis prevalence for elimination and eventual eradication 
(Mbah et al., 2013; Lo et al., 2015; Tambo et al., 2017; Ndassi et al., 2019). There are many 
personal and community factors that affect praziquantel coverage in any MDA programme 
such as socio-political set-ups with in communities, culture, religious beliefs, knowledge, age 
groups, mode used (central or door-door distributions), gender, comorbidities, distance from 
distribution centres and availability of supervision (Dabo et al., 2013). Ill people tend to seek 
medical attention more readily and some religious sects do not allow members to seek modern 
medical help. If school based distribution modes are used certain clusters wont access 
praziquantel especially in most sub-Saharan countries with many communities with poor 
school enrolments/coverage (Turner et al., 2017). In a study done in Nigeria; community based 
delivery was found to be the best mode of distributing praziquantel as it achieved 72.25% 
coverage compared to school (44.30%) or health facility (28.50% ) based modes (Mafe et al., 
2005). Direct observation, as might happen when medical supervision is available, increases 
compliance. Typically participation in mass drug programmes is better with males, school 
going children and those who have participated before (Tallo et al., 2008).  
Many variable risk factors have been associated with S. haematobium infection such as age 
group, location or area of residence, education level, occupation, source of water, gender, 
frequency of stream activities and socioeconomic class (Ndassi et al., 2019). The findings of 
this study have highlighted age and location as important factors in determining 
schistosomiasis prevalence. The study has also established that prevalence in rural and farming 
communities within endemic areas is similar between boys and girls. The lack of significance 
differences in infection levels between boys and girls is likely because most water-related 
chores and recreational activities are similar and often overlap within the age groups studied in 
many rural communities. Thus similar prevalences are expected in boys and girls; differences 
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are expected in adults and gender role differences become more marked. Thus elimination and 
eradication programmes should not discriminate based on gender. The World Health 
Organization’s set goals of controlling morbidity by 2020 and eliminating schistosomiasis as a 
public health problem by 2025 in many communities is achievable only if as highlighted above 
all inclusive approaches are applied especially in moderate to high prevalence regions like most 
of sub-Saharan Africa which house 85% of those infected (Taylor, 2008; French et al., 2018; 
Toor et al., 2018). Programmes such as sustained praziquantel treatments or 
chemoprophylaxis; development of more sensitive diagnostic tools; potential vaccine 
candidate development; enhanced snail control; WASH and health education can lead to 
elimination and eradication of schistosomiasis (Inobaya et al., 2014; Bergquist et al., 2017; 
Secor and Colley, 2018; Toor et al., 2018). There is still need for more financial and human 
resources as well as significant sustained political will if significant impact is to be made in the 
fight against schistosomiasis in Africa (French et al., 2018). It is also important to stress that 
risk factors for schistosomiasis are often variable from community to community hence the 
need for research supported community specific guidelines rather than generic approaches for 
all if elimination of the infection is to be realized in this generation (Bergquist et al., 2017). 
5.2. General limitations  
Some participants were not willing to provide blood for genotyping experiments. Of those 
willing (or willing guardians) some were unable to provide adequate blood for both genotyping 
and cytokine plasma level assessments especially in the pre-school age group. Resources and 
time limited the number of cytokines to be investigated as well as number of children to recruit. 
The limitations stated does not invalidate the important conclusions drawn from the study as 
the cytokines investigated are representative and the children numbers were well above 
calculated sample sizes.    
5.3. Overall conclusions  
Prevalence of S. haematobium in endemic rural and farming communities of Zimbabwe is 
similar between boys and girls. The overall prevalence of schistosomiasis observed (17.1%) 
puts the regions within the moderate range (10 – 49% prevalence). Age and location are 
important risk factors for schistosomiasis in children living in endemic regions. The older the 
child the higher the risk of getting infected by S. haematobium (10.5% in 0-5; 24.0% in 6-10 
and 30.7% in 11-15; p = 0.000).  IL-10 -1082 G/A, IL-10 -819 C/T and TNF-α -308 G/A single 
nucleotide polymorphisms are not significantly associated with susceptibility to S. 
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haematobium infection. TNF-α genotypes AA, GA and GG are associated with high, moderate 
to high and low production of TNF-α respectively. IL-10 TT, CT and CC genotypes are 
associated low, moderate and high IL-10 plasma levels respectively. Higher TNF-α and lower 
IL-10 serum levels are protective against schistosomiasis.  
Cytokine production is subject to many regulatory factors and the resultant levels circulating 
are a direct result of those opposing factors. Thus genotypic association with disease 
susceptibility and severity is a complex interplay of factors, where SNPs are one factor. A 
critical balance between TNFα and IL-10 is essential in determining susceptibility, morbidity 
and immunity to S. haematobium. Low IL-10 and high TNF-α leads to severe morbidity and/or 
severe immunopathological condition. Low TNF-α and/or high IL-10 leads to susceptibility, 
low immunity and higher chances of chronic infection. Thus an optimal balance of TNF-α and 
IL-10 levels is required for one to be immune and also protected against severe pathology in 
case one is infected of S. haematobium. Praziquantel treatment reduces infection burdens 
among children. 
5.4. Implications and recommendations 
 Inclusion of all age groups in non-gender specific prevention, management and control 
programmes in children will yield more positive results. 
 Future studies which include many cytokines and all possible single nucleotide 
polymorphisms known to influence cytokine gene expression will give a better picture 
on susceptibility and immunity to schistosomiasis and/or other helminthic infections.  
 Regular prevalence and infection intensity studies to help monitor and evaluate 
effectiveness of mass drug administration activities and well as checking age groups at 
high risk who might have been excluded.  
 Regular risk factor assessments as this will help in shaping control and elimination 
programmes. 
 Zimbabwe and indeed other nations should learn from past experiences and avoid 
overreliance on treatment/curative approach, but rather combine this with snail control 
and WASH programmes.  
 Other risk factor corrected genotyping and plasma cytokine level assessments could 
also help determine the existence or inexistence of association between certain 
genotypes (of TNF-α, IL-10 and/or other cytokines) and susceptibility to S. 
haematobium infections.  
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 Other cytokine and T-cell stimulation studies may provide more conclusive linkages 
between infection and cytokine responses in settings that are endemic for multiple 
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SPECIMEN STORAGE INFORMED CONSENT FORM 
 
STUDY TITLE: 
ROLES OF SINGLE NUCLEOTIDE POLYMORPHISMS IN THE PROMOTOR 
REGIONS OF TUMOR NECROSIS FACTOR-α AND INTERLEUKINE-1O GENES 
IN SCHISTOSOMA HAEMATOBIUM INFECTION SUSCEPTIBILITY 
 
Protocol Version: Ver1. 01.11.2012 
SPECIMEN STORAGE  
Consent Version  
(English) 
 
PRINCIPAL INVESTIGATOR: Mr A. Marume 
PHONE: 0772687090 
INTRODUCTION: 
You have decided to take part in the investigational research study named above, sponsored by 
the University of Zimbabwe and Ministry of Health & Chid Welfare.  While your child is in 
this study, blood 2.5 – 5 mls will be collected from your child. You are kindly being asked to 
agree to the storage of these samples for use during the study and after the study has ended. 
We may also ship these samples to another laboratory outside Zimbabwe if the need comes. 
This consent form gives you information about the collection, storage, and use of these 
UNIVERSITY OF ZIMBABWE 
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samples.  These samples will be useful in the first next 5 years the Mass Drug Administration 
of praziquantel research programme is running. The study staff will talk to you about this 
information.  Please ask if you have any questions.  You will be asked to sign or make your 
mark on this form to indicate whether you agree to have your child’s samples stored and tested.  
You will be offered a copy of this form to keep. 
YOUR PARTICIPATION IS VOLUNTARY: 
Allowing your samples to be stored is completely voluntary.  You may decide not to have any 
samples stored other than what is needed to complete this study and still be in this research 
study or any future study. 
Even if you decide now that your samples can be stored for the duration of the research, you 
may change your mind at any time.  If this happens, you must tell the study staff that you have 
changed your mind.  If you decide not to have your samples stored or used for future research, 
they will be destroyed at the end of the study.   
PURPOSE: 
The specific research to be done on your blood samples will be to analyse for markers of 
allergic reactions after treatment.   The samples will only be used to look for antibodies as 
markers of reaction and effect of treatment on the infections, damage caused by infection, or 
how your body reacts to the infection.  For example, the tests may look at cells, proteins, and 
other chemicals in your body.  Tests may also examine your genes (DNA), since they might 
affect your response to parasitic infection in important ways.  For example, your genes may 
make you more or less susceptible to becoming infected, your responses to infection or to 
treatment stronger or weaker, or make development of allergic reactions progress faster or 
slower.  No other kinds of genetic test will be done by anyone on your stored specimens without 
first explaining the test to you and obtaining your permission. 
The study researchers do not plan to contact you or your regular doctor with any results from 
tests done on your stored samples.  This is because research tests are often done using 
experimental procedures, so the results may not help for making decisions on managing your 
health.  In the very rare case that a specific test result gives important information about your 
health, the researchers will contact you.  If you wish to be contacted with this type of test result, 
you must give the study staff any change to your contact information.  If you have a regular 
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doctor and you want the study staff to tell this doctor your child’s test results, you must give 
the study staff your doctor’s contact information. 
Your samples will not be sold or used directly to produce commercial products. 
Research studies using your samples will be reviewed by the Medical Research Council of 
Zimbabwe. 
PROCEDURES: 
Each time your child’s blood is drawn, up to 5 mL (which is about 1.5 teaspoons) of the sample 
may be stored.  For each sample of blood, part of the sample will be tested immediately and 
the rest will be stored. 
Your blood will be stored safely and securely in a storage facility at the University of 
Zimbabwe-Biochemistry Department.  Only the people who work at the facility and approved 
researchers will have access to your samples.  The people who work at the facility will not have 
any information that identifies you.  The approved researchers may be given information about 
you such as your age and sex, but they will not be given your name or any other information 
that identifies you. Your samples may be shipped to approved researchers who work outside 
of Zimbabwe, if the need arises for some specialized assays not available in Zimbabwe. There 
is no time limit on how long your samples will be stored but we anticipate during duration of 
the MDA. 
RISKS and/or DISCOMFORTS: 
There are few risks related to storing your samples.  When tests are done on the stored samples 
there is a rare but possible risk to your privacy.  It is possible that if others found out information 
about you that is learned from tests (such as information about your genes) it could cause you 
problems with your family (having a family member learn about a disease that may be passed 
on in families). 
POTENTIAL BENEFITS: 
There are no direct benefits to you from having your child’s samples stored.  You and others 






To keep your information private, your samples will be labelled with a code that can only be 
traced back to your study clinic.  Your name, where you live, and other personal information 
will be protected by the study clinic.  When researchers are given your stored samples, they 
will not be given your personal information. Every effort will be made to keep your personal 
information confidential. 
Efforts will be made to keep your study records and test results confidential. You will be 
identified by a code, and personal information from your records will not be released without 
your written permission.  Any publication of this study will not use your name or identify you 
personally.   
PROBLEMS OR QUESTIONS: 
For questions about the storage of your samples, contact: 
 The PI: Amos Marume 
Paraclinical Department,  
University of Zimbabwe 
Churchill/University Ave 
P.O. Box MP 167 
Mount Pleasant, Harare 
Ph: 0772687090 
For questions about your rights as a research subject, contact: 
 Medical Research Council of Zimbabwe 
National Institute of Health Research  
Cnr Mazoe Street/ Josiah Tongogara Avenue 
Harare 
Ph :+263 4 791792, 791193 




CONSENT FOR SPECIMEN STORAGE  
Please carefully read the statements below (or have them read to you) and think about your 
choice.  No matter what you decide it will not affect whether you can be in the research study, 
or your routine health care. 
________ I agree to have samples of my child’s blood sample, stored and used for future 
testing related to allergy & autoimmunity. 
________ I agree to have samples of my child’s blood sample, stored and used for future 
testing related to allergy and autoimmunity.  However, I do not agree to have genetic testing 
performed on my samples. 
________ I do not agree to have samples of my child’s blood, stored and used for future 
testing related to allergy and autoimmunity. 
 
   
Name of Child (please print)   
 
    ____________________________________ 
Parent’s/Guardian’s Name (print)  Signature or Mark and Date 
 
   ____________________________________ 
Study Staff Conducting    Study Staff Signature and Date 
Consent Discussion (print) 
 
   ____________________________________ 




Appendix 6: Informed consent form for parental consent (Shona version) 





KUONGORORWA KEROPA REVANA VARIKURAPWA CHIRWERE 
CHECHIPFUNGA 
 
Mutungamiri wechirongwa: Mr Amos Marume (MSc)-0772687090 
Vatevedzi : Professor Takafira Mduluza, [PhD]- 0773633682 
       Dr J. Mann [PhD] 
 
Zvamunofanira kuziva nezvechirongwa ichi: 
 Tinokupai   chibvumirano  ichi  kuti muverenge  pamusoro pechinangwa,  
zvingangonetsa,  uye  nezvingangobatsira  muongororo iyi. 
 Zvirongwa  zvinoitwa zvinozobva  pane  ruzivo rutsva rwakanakisa rwatinenge  
tavanarwo 
 Chinangwa  chikuru  cheongororo  ndechekuwana  ruzivo rutsva  runozobatsira  pane 
ramangwana. 
 Hatingavimbisi  kuti ongororo iyi ichakubatsirai. 
 Munekodzero   yekuramba  kupinda/ kuve , kana yokubvuma  kupinda  izvozvi, uye  
yekushandura  pfungwa dzenyu pamberi  apo. 
 Chero  sarudzo  yamaita, hazvikanganisi  mabatirwo  enyu  enguva dzese 
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 Ndapota  nyatsodzverai  chibvumirano  chino nemazvo.  Bvunzai  mibvunzo  musati  
maita  sarudzo- hamumanikidzwi  kupinda. 
Chinangwa  cheongororo 
Muri kukumbirwa  mvumo yekuti mwana wenyu apinde  muongororo  iyi nokuti  muri  
mubereki/ munhu  mukuru  anogara  mudunhu  rino.  Muongororo/  mutsvakiridzo  iyi  tiri 
kuedza  kuona  zvinoitika kana  munhu  anwa mapiritsi anorapa bharaziya . Vana vari 
muzvikoro ndivo vachange vachipihwa mapiritsi aya, zvichireva izvo vanogona kubuda 
munyawiri muviri wese.    Isu vechirongwa chino tinoda kuongorora zvinokonzeresa 
munyawiri uyu. 
Mafambiro echirongwa 
Kana  mabvumidza mwana  kupinda  muongororo/tsvakirodzo  iyi  muchange  murimumwe  
wechikwata  chevanhu   vari munzvimbo dzakasiyasiyana vachange vachimirira vamwe vavo 
nezveongororo iyi yekuti vamwe vanobuda munyawiri asika vamwe hapanachinoitika. 
Tichabvunzazve vana vechikoro ava kuti tigoziva nzvimbo dzavanopinda mumvura. Izvi 
zvinotibatsira kuti tigoongorora kunobva chirwere ichi chebharazuya. 
Zvingangonetsa 
Hapana  zvinganetsa  pakupinda  muongororo  iyi.  Hurukuro  ingangotora  maminitsi mashanu 
kanasvika gumi enguva  yavena. Tichatorazve ropa ringanhoita sipunu rimwe kana maviri ekuti 
tizoshandisa kuongorora zviratidzwa zvwnyawiri urwu. 
Zvamunotarisirwa  kuwana 
Hapana  chatingati  muchawana  semuripo  nekuva  kwenyu  muongororo/tsvakiridzo  iyi. 
Muchawana  ruzivo  rutsva   runogona  kukubatsirai  kuchengetengetedza  mhuri  yenyu  iri 
mutano.  Zvekare,  pfungwa  dzenyu  nezvamakasanganirana nazvo  zvingangozobatsira  kuti 
kuve  nezvirongwa    zvirinani  zveutsana/kushambidzika  munharaunda yenyu kana  kune  
dzimwe  nzvimbo  dzenyika. 
Muripo 





Zvichabuda  zvitsva  muongororo 
Tichagoverana  nemi zvichawanikwa  muongororo  ino  uye  zimwe  zvitsva zvatinenge tawana  
pamusoro  pe tsvakiridzo iyi [yebharaziya nekurapwa kwayo nekubuda munyawiri]. 
Kuchengetedzwa kwezvinyorwa 
Tichanyora  pasi  zita  nekero  yenyu, nozvimwewo zviri maererano  nemi  pamapepa.  Hapana  
mumwe munhu   anogona kuona  zvinyorwa izvi  kunze  kwevari  muongororo.  Tichashandisa  
nhamba  kwete   zita,  kuti  vamwe  vakuzivei. Magwaro  ose  ane  zita nekero   nezvimwe zviri 
maererano  nemi zvamuno tiudza  zvinochengetedzwa  zvakakiyirwa,  pane  dzimwe  nguva  
vaongorori   vemitano yeongorori  vangade  kuona  kuti  ongororo iri  kuitwa  nemazvo  here,  
ava  ndivo vangazotarisa   mapepa  aya.  Vanhu  ava  vanosanganisira   veMedical  Research  
Council  of  Zimbabwe kana kuti VeUniversity of Zimbabwe.  Vese  ava  vanosungirwa  
kuchengetedza  mazita  enyu  akavandika .  kuchengetedzwa  kwakasimbisiswa 
hatingakukomakedze nekuti  mapepa emaresearch /ongororo  haangadziviswi  kana achidiwa   
navehurumende   kana  vematare  emutemo. Tichaedza nepatinogona kuchengetedza  zviri  
maererano  nemi  zvakawandika.  Zvinobuda semhinduro  yeongororo  iyi  kana  
zvinoshambadzirwa, hazvibudi   zvine mazita  enyu  kana  remwana  kana  zvimwe  zvinoita  
kuti muzivikanwe  kuti  makanga  muri  mune  chino  chirongwa. 
 Kuda  kwenyu 
Mwana haamanikidzwi  kupinda  muongororo  iyi.  Kana  masarudza  kuti apinde  muongororo  
iko  zvino  makasununguka  kumuti abude  muongororo  iyi  chero  nguva. 
Kana  muine  mibvunzo  monogona  kundibvunza  ndakasununguka  kuipindura.  
Munogonawo  kubvunza  vakuru  vakuru [Professor Takafira Mduluza] veongororo  vane  
mazita  akanyorwa  pazasi  apa  kana  paine   zvamusinganzwisisi  maererano  neongororo  iyi  
ikozvino  kana  mave  muongororo 
Ndivanaani  vandinofonera  kana  ndiine  mubvunzo  kana  dambudziko 
Kana  muine  mibvunzo  maererano  neongororo  taurai  navakuru  veongororo  vanonzi  





Kana  muine mibvunzo  nezvekodzero  dzenyu  muchiongororo,  ridzai  rinhare  kune  
veMedical  Research Council of  Zimbabwe  
Josiah Tongogara/Mazoe  Street 
Causeway, Harare 
Telephone [04 791  193/ 7907 15/791791] 
 
Zvinorevei  kunyora [kusaina]  zita rako 
Ini , nyakusaina  pazasi, ndaudzwa  chinangwa, mafambiro,  zvingangonetsa  
nezvingangobatsira  muongororo  iyi.  Ndapihwa  rimwe  reiri  gwaro  rekugara naro.  
Ndapihwa  mukana wekubvunza  mibvunzo  chero nguva ipi  zvayo.  Ndazvisarudzira  uye 
ndabvuma kuti mwana ave  muongororo  iyi. Isarudzo yangu  kuti mwana abude  muongororo, 
ndinoziva  kuti hazvikanganise  basa  rangu kana chinzvimbo  changu  munharaunda. 
Ndinovimbisa   kuti ndichatevedza  zvandinenge  ndakumbirwa  kuita  navashandi,  navakuru  
vakuru veongororo  iyi. Ndinovimbisa kuudza  vashandi veongororo  pakare  pakarepo  kana  
ini  ndiine  zvinetswa pandinenge ndiri  muongororo. 
  
Zuva ramurikusainira mwana kupinda  muongororo,  zvichireva zuva  ranhasi, 
RINOFANIRWA  kunge  riri  mukati  memazuva  akaratidzwa  pachidhindo  chiri  
papepa  rimwe  nerimwe.  Mazuva  akaratidzwa  aya  anotaridza kuti  pepa rino  riri 
kufambiswa  munguva  yakatenderwa,  kureva  kuti  muchange  muri muongororo  iyi. 
 
 
   
Zita remwana (Nyorai nemavara makuru)   
 
    




     
Zita kana chiratidzo chearikumirira mwana Zuva nenguva  
 
  
Hukama nemwana arikupinda muchirongwa 
 
    
Hwitinesi – pane avo vasingagoni Zita remumiririri arikutora bvumo ino 
                  kuverenga kana kunyora 
  
Rimwe  remagwaro  echibvumirano  ichi  rakasainiwa  rinofanirwa  kuti 1]  
richengetedzwe  mufaira  nemukuru  mukuru weongororo ,2]  ripihwe  kune  uyo  
asarudza  kupinda  muongororo  ne3]   riiswe  mufaira  rekurapwa  kweuyo  asarudza  













Appendix 7: Informed consent form for parental consent 
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INFORMED CONSENT FORM 
FOR PARENTAL CONSENT 
PROJECT TITLE 
ROLES OF SINGLE NUCLEOTIDE POLYMORPHISMS IN THE PROMOTOR 
REGIONS OF TUMOR NECROSIS FACTOR-α AND INTERLEUKINE-1O GENES 
IN SCHISTOSOMA HAEMATOBIUM INFECTION SUSCEPTIBILITY 
Principal Investigator: Mr A. Marume (MSc)-0772687090 
Co-Investigator(s): Professor Takafira Mduluza, [PhD]- 0773633682 
    Dr J. Mann [PhD] 
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ADD THE FOLLOWING PARAGRAPH TO ALL CONSENT FORMS  
MORE THAN TWO (2) PAGES LONG (BEFORE ADDITION OF THIS PARAGRAPH) 
 
What you should know about this research study: 
 We give you this consent so that you may read about the purpose, risks, and benefits 
of this research study. 
 
 Routine care is based upon the best known treatment and is provided with the main 
goal of helping the individual patient.  The main goal of research studies is to gain 
knowledge that may help future patients. 
 
 We cannot promise that this research will benefit your child.  Just like regular care, 
this research can have side effects that can be serious or minor. 
 
 You have the right to refuse to allow your child to take part, or agree for your child 
to take part now and change your mind later. 
 
 Whatever you decide, it will not affect your child’s regular care. 
 
 Please review this consent form carefully.  Ask any questions before you make a 
decision. 
 







 You are being asked to allow your child to participate in a research study of 
susceptibility to bilharzia and its treatment.  The purpose of the study is to assess if there is 
any genetic association of cytokine gene polymorphism and susceptibility to 
schistosomiasis. Your child was selected as a possible participant in this study because this is 
the age that is commonly found infected with bilharzia and also their health and learning 
ability is greatly affected. Also the children at this school will get the treatment from the 
currently bilharzia treatment underway throughout the country. We need to monitor their health 
status before and after the treatment is given. The information is important in our country for 
any likely development of allergy as caused by the worms when they die after treatment. We 
would like to get information for preparedness in the future activities of the mass treatment 
exercise by The Ministry of Health and Child Welfare. This study will have a total of about 
700 children recruited to represent others in the schools and we will have school children 
recruited from selected schools in other provinces. 
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PROCEDURES AND DURATION 
 If you decide to allow your child to participate, your child will be asked a few questions 
taking less than 5 minutes so that we know where they get in contact with water in rivers or 
streams and if there are things that cause allergy in their daily lives. Thereafter the child will 
be asked to provide urine and stool in small bottles so that we will be able to diagnose if they 
are infected with bilharzia and some worms. This process will be done over 3 consecutive days 
so that we don’t miss any infection. A small blood sample 2,5 -5 mls will be taken from them 
and will used if they are infected with malaria and if there are markers that show any reaction 
to agents that cause allergy.  The same procedure will be conducted before they receive 
treatment and 6 weeks after treatment to observe any changes to treatment and the development 
of allergic markers. We will monitor the children for any development of allergy throughout 





RISKS AND DISCOMFORTS 
  The study does not involve any risks besides a temporary discomfort that may be 
experienced by child while taking venous blood due to the needle prick. However, this 
procedure is a common and normal as practised at most health centres and will be performed 
by qualified medical personnel from the Ministry of Health.  
 
BENEFITS AND/OR COMPENSATION 
Your child will benefit from this program by being one of the few children that will receive 
close monitoring and examination from the mass treatment of bilharzia and worm throughout 
the country. The study team cannot manage to examine closely everyone, the reason we have 
to select a few to represent others.  
   
ALTERNATIVE PROCEDURES OR TREATMENTS 
 Praziquantel is the only drug available for treating bilharzia. Every child will receive 




 If you indicate your willingness for your child to participate in this study by signing 
this document, any information that is obtained in connection with this study that can be 
identified with your child will remain confidential and will be disclosed only with your consent, 
and when appropriate, your child’s permission. Under some circumstances, the MRCZ and the 
local Institutional Review Board may need to review patient records for compliance audits. 
 
ADDITIONAL COSTS 




IN THE EVENT OF INJURY 
 In the event of injury resulting from your child's participation in this study, treatment 
will be offered by the study.  
 
VOLUNTARY PARTICIPATION 
 Participation in this study is voluntary.  If you decide not to allow your child to 
participate in this study, your decision will not affect your or your child's future relations with 
research group and this institution, its personnel, and associated hospitals.  If you decide to 
allow your child to participate, you and your child are free to withdraw your consent and assent 
and discontinue participation at any time without penalty. 
 
ADDITIONAL ELEMENTS  
None 
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OFFER TO ANSWER QUESTIONS 
Before you sign this form, please ask any questions on any aspect of this study that is unclear 
to you.  You may take as much time as necessary to think it over. 
 
AUTHORIZATION 
YOU ARE MAKING A DECISION WHETHER OR NOT TO ALLOW YOUR CHILD TO 
PARTICIPATE IN THIS STUDY.  YOUR SIGNATURE INDICATES THAT YOU HAVE 
READ AND UNDERSTOOD THE INFORMATION PROVIDED ABOVE, HAVE HAD 
ALL YOUR QUESTIONS ANSWERED, AND HAVE DECIDED TO ALLOW YOUR 
CHILD TO PARTICIPATE. 
 
The date you sign this document to enrol your child in this study, that is, today’s date, MUST 
fall between the dates indicated on the approval stamp affixed to each page.  These dates 
indicate that this form is valid when you enrol your child in the study but do not reflect how 
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long your child may participate in the study.  Each page of this Informed Consent Form is 
stamped to indicate the form’s validity as approved by the MRCZ. 
 
    
Name of Parent (please print)  Date 
 
     
Signature of Parent or legally authorized representative Time  
 
  
Relationship to the Participant 
 
  
Signature of Witness Signature of Research Staff 
(Optional)  
 
 YOU WILL BE GIVEN A COPY OF THIS CONSENT FORM TO KEEP. 
 
 If you have any questions concerning this study or consent form beyond those answered 
by the investigator, including questions about the research, your rights as a research Participant 
or research-related injuries; or if you feel that you have been treated unfairly and would like to 
talk to someone other than a member of the research team, please feel free to contact the 






Appendix 8: Manuscript accepted and proofreading done - Southern African Journal of 
Infectious Diseases 




Ref. No.: 11 
Manuscript title: IL-10 and TNF-α promoter region polymorphisms and 
susceptibility to urogenital schistosomiasis in young Zimbabwean children 
living in Schistosoma haematobium endemic regions 
Journal: Southern African Journal of Infectious Diseases 
****************************************************************** 
Dear Dr Amos Marume 
 
You will be pleased to know that your manuscript has been accepted for 
publication on 23-06-2020. 
 
We would like to confirm that your manuscript has now been sent to our 
publishing department for finalisation. 
 
Kindly note: 
1. If you need to make contact with the publisher during the finalisation 
stage of your manuscript, kindly contact us per email or phone. Your new 
publisher contact will be Jana Venter, email: publishing@sajid.co.za and 
telephone extension: 507  
2. The finalisation procedure works as follows:  
(a) The first stage is the language editing that is returned to the 
corresponding author for review. This will be the final opportunity for the 
corresponding author to make text changes to the manuscript.  
(b) At a later stage, the editorial staff will send the corresponding author 
one set of galley proofs, at which time the author will have two working 
days to mark any typographical errors.  
3. Manuscript tracking is available on the submitting authors’ journal 
profile. The submitting Author could visit their home page frequently to 
assess the stage of the manuscript. 
 
Kind regards, 
AOSIS: Tanien Botes 
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aosis@ajlmonline.org 
 






Ref. No.: 1138 
Manuscript title: Cytokine TNF-α -308 G/A and IL-10 -819 C/T Promoter 
Region Single Nucleotide Polymorphisms Effects on Susceptibility to 
Urogenital Schistosomiasis in Pre-school Children in Zimbabwe 
Journal: African Journal of Laboratory Medicine 
****************************************************************** 
Dear Dr Amos Marume 
 
Your submission has been received by the journal and will now be processed 
in accordance with published timelines.  
 
Processing time guidelines are available under the journal’s ‘About’ 
section, however, please note that each submission is assessed on its 
individual merit and in certain circumstances processing times may differ. 
 
You can check the status of your submission in three ways: 
- Journal Website: login to your account at 
https://ajlmonline.org/index.php/ajlm/author/submission/1138. 
- Publisher Enquiry Service: telephone numbers are +27(0)219752602 and/or 
0861000381. 
- Publisher FAQ and Email Service: visit the Publisher FAQ and Email service 
at https://publishingsupport.aosis.co.za/index.php 
 
You will receive additional emails from the journal as your submission 




African Journal of Laboratory Medicine 
________________________________________________________________________ 
African Journal of Laboratory Medicine 
https://ajlmonline.org 
 
If you require immediate assistance, please contact the AOSIS Publishing: 
 
Tel: RSA: 0861000381 - Intnl: +2721 975 2602 
Fax: +27 (0)86 5004 974 
Support email: publishing@aosis.co.za 
Business hours are weekdays between 8:00am-16:30pm 
Confidentiality: The information contained in and attached to this email is 
confidential and for use of the intended recipient. This email adheres to 
the email disclaimer described on www.aosis.co.za. 
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Ref. No.: 2313 
Manuscript title: Overview of Schistosomiasis Chemotherapy using 
Praziquantel 
Journal: African Journal of Primary Health Care & Family Medicine 
****************************************************************** 
Dear Mr Amos Marume 
 
Your submission has been received by the journal and will now be processed 
in accordance with published timelines.  
 
Processing time guidelines are available under the journal’s ‘About’ 
section, however, please note that each submission is assessed on its 
individual merit and in certain circumstances processing times may differ. 
 
You can check the status of your submission in three ways: 
- Journal Website: login to your account at 
https://phcfm.org/index.php/phcfm/author/submission/2313. 
- Publisher Enquiry Service: telephone numbers are +27(0)219752602 and/or 
0861000381. 
- Publisher FAQ and Email Service: visit the Publisher FAQ and Email service 
at https://publishingsupport.aosis.co.za/index.php 
 
You will receive additional emails from the journal as your submission 




African Journal of Primary Health Care & Family Medicine 
________________________________________________________________________ 
African Journal of Primary Health Care & Family Medicine 
This journal is available at https://phcfm.org 
 
If you require immediate assistance, please contact the AOSIS Publishing: 
 
Tel: RSA: 0861000381 - Intnl: +27 (0)21 975 2602 
Fax: +27 (0)86 5004 974 
Support email: publishing@aosis.co.za 
Business hours are weekdays between 8:00am-16:30pm 
 
 
 
